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ABSTRACT 
 
Title: Clinical Profile of Children with Extra Cranial Germ Cell Tumors 
Aim/Objectives:  
To assess the clinico-pathological profile and the long term effects of treatment in children, with 
extracranial germ cell tumors (GCTs).  
Materials and Methods: 
All children below the age of 16 years who presented to the department of Paediatric Surgery 
with GCTs between January 2003 and December 2012 were included in this study. This was a 
retrospective study looking at the patient data base. All eligible patients were informed by mail 
and phone by the investigator and requested to attend the outpatient department for follow up. 
Data was analyzed using descriptive statistical methods for continuous and categorical variables. 
Binary logistic regression was used to look at risk factors, and Kaplan Meier curves for overall 
survival and event free survival.  
Results: 
107 children with GCTs were studied for the period between 2003 to 2012, 64% were female and 
36% were male, 56% were below 5 years of age. A majority were found to have ovarian GCTs 
(28%) followed by sacrococcygeal (23%) and testicular (15%) tumors.  Malignancy was found in 
46%, the commonest being yolk sac tumor.  Elevated Alpha feto protein was found in all 
children with malignancy.  Surgery alone or in combination with chemotherapy was used to treat 
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these tumors. Overall survival and event free survival for malignant GCTs was 85.2% and 75.9% 
respectively. Median survival was 44 months. 
 
Conclusions:  
GCTs are rare tumors which occur at many different sites. They are more common in females 
and have different age peaks for different sites. Non gonadal sites predominate in early 
childhood, while gonadal GCTs are more common during the later part of childhood and 
adolescence. Benign tumors are more common. Malignancy can occur,  with Yolk Sac tumors 
being the commonest. Multimodality treatment with surgery and chemotherapy has excellent 
results in malignant tumors. Long term follow up is advisable for all patients who have GCTs. 
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INTRODUCTION 
 
Germ cell tumors (GCTs) are a rare group of benign and malignant tumors which can occur at 
many different sites. These can be both gonadal and extragonadal. They occur in the para-axial 
locations like sacrococcygeal area, gonads, retroperitoneum, mediastinum, neck and pineal gland 
in order of frequency, due to the arrest or abnormal migration of primitive germ cells.  
These tumors represent about 1-3% of all childhood tumors, and about 8-10% of all paediatric 
solid tumors.  There is large spectrum of these tumors from the mature teratoma to the highly 
malignant embryonal carcinoma.  Benign teratomas are the commonest although upto 30% 
malignancy has been described in various series. 
Tumors of the extragonadal sites are the commonest during infancy and early childhood, and 
gonadal sites predominate during later childhood and adolescence. A bimodal peak has been 
described in various studies, but others have found a varying age peak for different sites. These 
tumors are commoner in females.  
With the advent of highly sophisticated imaging like Magnetic resonance imaging (MRI)  and 
Computed Tomography (CT) scan and tumor markers like Alpha feto protein (AFP) and Human 
chorionic gonadotropin (βHCG), the pick-up rate of malignancy has increased and these tumors 
now can be treated with proper diagnosis.  
Surgery alone is used for benign tumors. A combination of surgery and chemotherapy (both 
preoperative and postoperative) is used to treat malignant tumors. 
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In the pre-chemotherapy era, survival of patients with malignancy treated with surgery alone was 
rare. Some progress was made in the initial days where Vincristine, Actinomycin D and 
Cyclophosphamide (VAC) was used. Platinum based chemotherapy protocols in the 1980s and 
1990s using Cisplatinum, Bleomycin and Etoposide (PEB) or Carboplatin, Bleomycin, and 
Etoposide (JEB) are currently used as first line therapy and have improved survival immensely.  
Survival rates of almost 100% are recorded for children with low stage malignant gonadal GCTs. 
Survival rates of almost 90%-95% have been achieved with high stage gonadal GCTs. For the 
malignant extragonadal sites survival rates of 70-90% have been reported.  
We present the clinical profile of 107 patients between January 2003 and December 2012 who 
presented to the department of paediatric surgery with extracranial germ cell tumors. 
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AIMS AND OBJECTIVES 
 
1. To assess the clinico-pathological  profile of patients who have presented to the 
department of Paediatric Surgery with Extracranial Germ Cell Tumors 
 
2. To assess the long term effects of treatment (Surgery and Chemotherapy) in children with 
Extracranial Germ Cell Tumors 
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REVIEW OF LITERATURE 
 
Germ cell tumors (GCT’s) are tumors which arise from primitive germ cells. These are rare 
tumors which can occur anywhere in the body from the pineal gland to the genitourinary system. 
These tumors have a broad spectrum from the aggressive embryonal carcinoma to the benign 
mature teratoma. GCTs tend to occur in the midline or the para-axial locations of the body. This 
supports the theories of germ cell migration. Sacrococcygeal tumors are the most common, 
followed  by gonadal, mediastinal, retroperitoneal and  other rarer sites like the jaw, neck, 
vagina, and bladder.(1) 
At a gestational age of four weeks germ cells arise from the yolk sac endoderm of the fetus. At 
about the sixth week they reach the genital ridge via the dorsal mesentry. This migration is 
determined by c-kit receptors and stem cell factors. If the migration of these germ cells is halted 
or is along an different path, germ cells get deposited in these areas and can form tumors 
anywhere mainly  in the sacrococcygeal area.(2) 
 
Incidence and epidemiology 
Several studies have analyzed GCTs reporting an incidence between 0.3%-3% among all 
paediatric malignancies, and 8-10% for all paediatric solid tumors. There is a female 
preponderance with female to male ratio of 4-1.7:1. A higher incidence in females is thought to 
be due to higher number of ovarian tumors than testicular tumors.  There is no predilection 
described  to a specific geographic region or race.(1–8)  
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Embryology 
Several theories have been proposed to explain the origin and location of these tumors. Some 
investigators support the theory of migration of primitive germ cells along an altered path. 
Another theory proposes that the totipotent cells which originate in the primitive knot and 
primitive streak give rise to these tumors, which invaginate between the layers of the bilaminar 
disc to form the mesoderm.(9) 
 
Histology 
There is a broad spectrum of histologic types which are classified as follows. Teratomas, which 
can be either mature or immature, germinomas arise in the ovary, and their counterparts, 
seminomas arise in the testes. The endodermal sinus tumor or yolk sac tumor, choriocarcinoma 
and embryonal carcinoma are also part of this spectrum.(1) 
Telium proposed a holistic concept, a theory which speaks of germ cell tumors arising from 
totipotent primitive germ cells. These cells follow embryonic or extraembryonic differentiation. 
The tumors which follow extraembryonic differentiation are yolk sac tumors and 
choriocarcinoma. Yolk sac tumors secrete alfa fetoprotein (AFP) and choriocarcinoma, beta 
human chorionic gonadotropin (βHCG) respectively. Immature totipotent cells give rise to 
embryonal carcinoma. Teratomas are tumors which mimics organ structures of all germ layers in 
differentiation. The grade of immaturity is decided by the presence of neuroepithelial elements. 
Seminomas in males and dysgerminoma in females are tumors which represent undifferentiated 
germ epithelium. In contrast to adult germ cell tumors paediatric germ cell tumors do not 
develop from intratubular carcinoma in situ.(5) 
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Tumor Markers 
A common histology in malignant GCTs is yolk sac tumors or endodermal sinus tumor. They 
secrete alfa fetoprotein (AFP). AFP should be estimated at the time of presentation. Human 
chorionic gonadotropin (βHCG) is produced by choriocarcinoma. These tumors are rarer than 
yolk sac tumors. Persistently elevated levels of these markers or rising levels after initial decline 
suggests non responsive or recurrent tumors.(4) 
The human yolk sac produces alpha-fetoprotein (AFP), albumin, prealbumin, alpha-l-antitrypsin 
and transferrin. This was studied in cultured cells and nude mice which had transplanted tumor 
cells. Some proteins like alpha-fetoprotein and alpha-I-antitrypsin were synthesized by these 
cells. The production was studied in children with yolk sac tumor. Abnormally high levels of 
AFP were found in all these children. The other proteins were at normal levels.  This can be 
explained by the fact that proteins other than AFP are present in large quantities in sera of 
normal people. AFP is seen only in small quantities in normal people. AFP can be correlated  to 
the diagnosis and response to treatment for children with Yolk sac tumor. When the tumor is 
completely excised serum AFP reaches normal levels (0IU/ml) with a half-life of 4 days. In cases 
where only radiotherapy and chemotherapy has been used these remain elevated.(10) 
 
Genetics 
Malignant GCT tend to occur more in children with disorders of sexual differentiation(DSD), 
undescended testes, and Klinefelter’s syndrome associated with thoracic teratomas. Children 
with DSD have and increased risk of developing gonadoblastoma. Gonadoblastoma can undergo 
transformation to yolk sac tumor, dygerminoma, immature teratoma or choriocarcinoma.(4) 
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Chromosomal abnormalities have been found in children who have malignant germ cell tumors. 
Children with benign tumors who are less than 4 years old  have normal chromosomes.  A 
majority of children with malignant GCTs from both gonadal and extra gonadal sites have 
abnormalities of chromosome 3.  Girls with malignant ovarian GCTs had loss of 1p/gain of 1q. 
Among the boys with extragonadal GCTs, many have abnormalities of chromosome 21 and X 
chromosomes. Many have been found to have trisomy 21 and Klinefelter’s syndrome. Many 
chromosomal anomalies are seen in children with testicular GCTs. These include near-triploidy, 
loss of chromosomes 11, 13, and 18, and gain of chromosomes 7, 8, the X chromosome, and an 
isochromosome 12p.  In children with malignant GCTs deletion of 1p/gain of 1q and +3 are 
commonly seen.(11) 
 
Age Distribution 
A bimodal age distribution has been observed in germ cell tumors in some studies whereas 
others describe a different peak for different sites. There is a high incidence in early infancy and 
another peak seen after puberty. Majority of tumors diagnosed at birth are benign. Yolk sac 
tumor focus may be seen in a few. In early childhood yolk sac histology predominates. 
Seminomas and dygerminomas present after puberty. There is a high incidence of mixed GCTs 
in the form of embryonal carcinoma and choriocarcinoma. The incidence of GCT at non gonadal 
sites is high during infancy, whereas after puberty gonadal GCTs predominate.  In childhood 
most non gonadal tumors are seen in females. After puberty a majority non gonadal tumors are 
seen in males.(1,3,5,12) 
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Imaging 
A priority for diagnosis and management of germ cell tumors is good imaging. Imaging has been 
utilized in the initial diagnosis and also in the follow up of both benign and malignant germ cell 
tumors. With the advent of newer diagnostic modalities like the magnetic resonance imaging 
(MRI), and Positron emission Tomography (PET) the diagnosis, marking, treatment and follow 
up of these tumors has become easier. 
It is now possible to detect teratomas, especially the ones located in the sacral region antenatally. 
Fetal MRI has now been used to confirm the diagnosis based on ultrasound evidence.(13) 
Sacrococcygeal teratomas are easy to diagnose once they present antenatally or in the neonatal 
period as most are evident on clinical examination. However the ones which present after the 
neonatal period should be evaluated by CT or MRI to mark out the extent of intrapelvic 
extension as this definitely has a role to play in the extent of surgery and the outcomes of 
patients.(14) 
The use of thoracic and abdominal CT is considered a part of the protocol for children who are 
diagnosed to have testicular tumors. These scans delineate the retroperitoneal lymphnodes and 
can also be used to assess the possibility of metastasis in these. Lymph nodes which are greater 
than 2 cm are considered to be significant. CT is also used for follow up of such children as this 
can show the response to therapy.(15) 
Tumors of the ovary present with abdominal pain or a mass. Some of these also present with 
acute abdomen. Most of these children will undergo an ultrasound examination. There is no 
specific radiology finding to differentiate between a malignant or benign mass. Therefore in 
addition to radiology tumor markers should also be evaluated to make a correct diagnosis.(16) 
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Imaging is very important in intra-abdominal and retroperitoneal tumors. These present with an 
abdominal mass or abdominal distention. Some of these may have reached a massive size before 
a doctor is consulted. It may be difficult to establish the site of origin of these masses even on 
ultrasound. Thus CT scan and MRI along with tumor markers are very important to establish 
diagnosis and the origin of such tumors.(2) 
Mediastinal germ cell tumors are delineated by the use of highly advanced imaging like the MRI 
and CT scans. One can establish the site of origin and the related structures in the mediastinal 
germ cell tumors. Complete surgical extirpation may not be possible in mediastinal germ cell 
tumors and this can be evaluated on the imaging that is used. The follow up of the response to 
therapy can also seen on follow up imaging.(17) 
The tumors of the miscellaneous sites can be evaluated by CT scan MRI or ultrasound. The 
extent, involvement of vital structures can be seen on CT scan. MRI has the advantage of being 
radiation free and better for soft tissue diagnosis.(18) 
 
Classification 
GCTs are commonly classified using the World Health Organization (WHO) classification. 
According to WHO GCTs are classified into 7 pathological types. These are dygerminoma, yolk 
sac tumor(endodermal sinus tumor), embryonal carcinoma, polyembryoma, choriocarcinoma, 
teratoma and gonadoblastoma. Dysgenetic gonads may give rise to gonadoblastoma, which is 
included in GCTs although it contains Sertoli cell components. (1,6,8)    
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Staging  
There are various ways of staging GCTs. The Children’s oncology group staging is one of them. 
The TNM classification has also been used. There is a system of risk stratification of germ cell 
tumors depending on age, stage, presence of immature elements, and distant metastasis. This 
system has also been developed by the children’s oncology group (COG). Stage I is complete 
resection at any site including coccygectomy and negative tumor margins, stage II is microscopic 
residual disease, stage III is lymph node involvement with metastatic disease, gross residual 
disease, biopsy only, stage IV is distant metastasis including liver.(4) 
Testicular tumors are staged a little differently as their pattern of spread is mainly through lymph 
nodes. Stage I is limited to testes, completely resected by high inguinal, orchiectomy, no clinical, 
radiological, or histological evidence of disease beyond the testis. Stage II is transcrotal 
orchiectomy or microscopic disease in the scrotum of high in the spermatic cord <5cm from 
proximal end, stage III is retroperitoneal lymphnode involvement but no visceral or 
extrabdominal involvement, lymph nodes >4cm by CT or >2cm and <4cm with biopsy proof, 
stage IV is distant metastasis including liver.(4) 
Ovarian tumors have a different staging system. Stage I is limited to ovary, peritoneal evaluation 
is negative, Stage II is microscopic residual disease with no peritoneal involvement, Stage III is 
lymph node involvement with gross residual disease, and involvement of surrounding viscera, 
Stage IV is distant metastasis including liver.(4) 
 
Risk Stratification 
GCTs are now categorized into various risk strata to allow for more protocol based treatment.  
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Factors like age, site, type of histology, stage of tumor, whether the resection is complete and 
tumor markers like AFP and βHCG are used to stratify patients into risk groups in currently used 
treatment protocols. Such protocols have achieved a cure rate of over 80%. Low risk patients are 
now treated with a wait and watch policy or reduced chemotherapy. Patients who were 
previously thought to be high risk can have a favorable prognosis with treatment according to 
risk stratification.(19) 
Low risk tumors are Stage I gonadal and all immature teratomas which require surgery and 
observation. Intermediate risk are Stage II-IV testis and Stage II-III ovary  and stage I-II  
extragonadal which require surgery and 3 cycles of JEB chemotherapy, High risk tumors are 
Stage IV ovary and stage III –IV extragonadal tumors which require surgery and 4 cycles of 
chemotherapy.(4) 
The French Society for Pediatric Oncology developed specific prognostic criteria for children 
with malignant GCT’s. These included tumor markers, disease stage and primary site. The 
pediatric intergroup study found that age more than or equal to 12 years was the most important 
prognostic factor in children receiving platinum based chemotherapy.(8) 
 
Treatment 
Germ cell tumors can be benign or malignant. Those which are benign are treated with surgical 
excision alone. Multimodality therapy including chemotherapy, radiotherapy and surgery is used 
for malignant germ cell tumors. Chemotherapy can be used as neoadjuvant or preoperative 
chemotherapy, or post operative chemotherapy or both. Different tumor biology and histology 
cause these tumors to have variable response to chemotherapy and radiotherapy. Germinomatous 
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tumors respond well to both chemotherapy and radiotherapy. Non germinomatous tumors do not 
respond well to radiotherapy.(5) 
Excellent outcomes have been seen in clinical trials done for management of extracranial 
malignant germ cell tumors (GCTs) in the western world. In developing countries like India the 
outcomes are different. A delay in presentation, misdiagnosis and abandonment of treatment are 
factors which contribute to poor results.(8)  
Cisplatinum being introduced as a base for chemotherapy along with recent advances in surgery 
have improved results and prognosis in children with malignant GCTs. Adequate systemic tumor 
control is seen with platinum based chemotherapy. Recurrence may be seen if adequate local 
treatment is not given. Complete primary resection is possible in gonadal tumors, as these have a 
capsule which is well defined. Testicular GCTs are seen at a low stage of the disease. At sites 
where large tumors occur, like the sacrococcygeal and mediastinum, a primary resection may not 
be possible.  After adequately evaluating these tumors, with tumor markers and imaging, 
preoperative chemotherapy can be given followed by surgery. Local and regional hyperthermia 
has been seen to enhance the effect of chemotherapy on tumor control. In tumors which do not 
secrete tumor markers a biopsy is mandatory.(19) 
Several studies have been conducted in children to measure the effect of chemotherapy in 
advanced malignant germ cell tumors. Measurable disease remission has been seen in a majority 
of patients with regular chemotherapy protocols. There has been a dramatic improvement in 
survival and outcomes with the regimes followed now as compared to previously used regimes 
which included Methotrexate, Cytoxan and Dactinomycin.(19,20) 
The MAKEI the MAHO trials used Cisplatinum, Etoposide and Bleomycin (PEB) for treatment 
whereas the  UKCCSG GCII  used Carboplatin, Bleomycin and Etoposide (JEB) for its study. 
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Carboplatin has less cumulative renal and ototoxicity which is seen with cispaltinum. The 
following are the dosage regimens used (5) 
Drug Dosage Days 
Cisplatinum 20mg/m2 4,5,6,7,8 
Bleomycin 15mg/m2 1,2,3 
Etoposide 80mg/m2- 120mg/m2 1,2,3 
Carboplatin 600mg/m2 1 
 
Several other drugs like Ifosfamide 1800mg/m2 and Vinblastine 1mg/m2 have also been used in 
various other trials(5). PEB and more commonly JEB are used in our institution. 
 
Sacrococcygeal Teratoma (SCT) 
Sacrococcygeal teratoma is the most frequently diagnosed germ cell tumor. An incidence of 
1:25000 to1:35000 live births has been reported. According to literature it is predominantly seen 
in girls with a female to male ratio of 4:1. Three fourths of tumors present in the neonatal period, 
with most becoming evident by age 4 years.(1) 
Altman and colleagues developed the classification of SCT in 1974. Type I tumors are almost 
entirely external, type II are primarily external with a small presacral component, type III are 
primarily presacral with a small external component, and type IV are entirely presacral. The 
overall risk of malignancy is 13% to 27%, but a strong correlation of malignancy with age at 
presentation is apparent. Benign tumors are seen in greater than 90% of children younger than 
age 2 months but present in less than half of children older than 2 months at presentation.(21) 
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The resection of sacrococcygeal teratomas follows the principles described by Gross et al in 
1951.Complete removal of the tumor with excision of the coccyx, and resection which preserves 
the muscles and nerves are core. Some authors suggest early vascular control in tumors which 
are solid and very vascular. Some even suggest occlusion of the aorta, ligation of the internal 
iliac artery and the middle sacral artery in premature infants. Some authors suggest the surgery 
be performed in a supine position for good hemostasis and reducing respiratory compromise. 
The muscle layers can be distorted by large tumors. It is very difficult to preserve and re-
approximate these sphincter and gluteal muscles. Muscle stimulators can be very helpful at these 
times. The anal opening should also be placed properly in the perineum. Sometimes the anus can 
be placed posteriorly although within the sphincter. This poses problems in defecation. The skin 
closure is done in the Chevron fashion. A right angled flap has been described by Fishman et al 
which avoids scars below the gluteal crease and provides more tissue between the coccyx and 
anus.(1,4,22) 
A retrospective study done at Tanta University and its associated hospitals, evaluated 35 patients 
with SCT, from 1998 to 2008. They found that children who presented as neonates had benign 
tumors with no recurrence in a follow up of 3-8 years. In children who presented beyond 6 
months of age there was a high rate of recurrence.(14) 
A study in Nigeria found SCT to occur more commonly in girls with 60.9% presenting 
immediately after birth and 85% of these tumors were found to be benign. There was recurrence 
in 4%. All malignant tumours had a significant presacral component. The benign tumors were 
resected. This study found  61%  were type I, 24%  type II,  and 14% were type III.(22) 
In a review of SCT Noteworthy et al found that 84%  benign tumors. These benign tumors 
(mature and immature teratomas) presented externally (Altman type I) which helped in early 
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diagnosis and treatment. The immature tumors were larger than the mature teratomas and had 
malignant transformation in 16% patients. The malignant tumors like the  embryonal and 
anaplastic carcinomas had a delayed age at  diagnosis (average 21 months) and had a substantial 
presacral or endopelvic component (Altman types II–IV); this group had a bad prognosis with no 
survivors.(23) 
Some studies have reported a high proportion of Altman type IV tumors. A majority of such 
patients present beyond the neonatal period. Good imaging is required to delineate the extent of 
these tumors which may include pelvic MRI. A large majority can be excised via the sacral route 
but a preliminary colostomy with abdominosacral excision may reduce morbidity in very large 
tumors.(24) 
In a large study which followed up 117 patients with SCT, 25% were diagnosed prenatally, 63% 
at birth and 11% later in infancy. Resection was carried out via the sacral or abdominosacral 
route. 69% were mature teratomas, 20% were immature teratomas, and 11% were yolk sac 
tumors. Recurrence was seen in 2 patients with mature teratoma, and 7 with yolk sac tumor and 1 
with immature teratoma. There was 33% recurrence seen in children with yolk sac tumor who 
were given no chemotherapy. The children were treated with adjuvant chemotherapy and had a 
80% overall survival.(25) 
 
Testicular GCTs 
GCTs are rare in boys. They usually present as an enlarging testicular mass with or without 
associated hydrocoele. These children will need a scrotal ultrasound and tumor markers. A high 
orchidectomy is performed in boys with elevated tumor markers. This is followed by 
chemotherapy using the JEB protocol. Recurrence is assessed by tumor markers.(4) 
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Of the 34 testicular neoplasms in 33 boys studied by Abell and Holtz in 1963 over a 40 year 
period, 25 were germ cell tumors. All these boys were less than 12 years of age average being 17 
months. Embryonal carcinoma was diagnosed in 14 of these children and benign teratoma in 10 
children. One child had bilateral teratomas.(26) 
Testicular GCTs have a familial predisposition in1-2% of cases. Brothers of children with 
testicular GCTs have a 8-10 fold risk, fathers have a 4-6 fold risk and twin brothers have a higher 
risk of developing tumors. The Y gr/gr deletion and  mutations in PDE11A gene have increased 
risk of these tumors.(27) 
The testis is the second most common site for yolk sac tumor. In one study of 37 patients with 
endodermal sinus tumor of different parts of the body, 10 had the tumor in the testis. All these 
patients were treated with a combination of chemotherapy and surgery.  One patient had a 
retroperitoneal lymphadenectomy. All these patients were alive and well at follow up.(28) 
In its consensus guidelines the European Germ Cell Cancer Consensus Group has recommended 
that primary surgery which can be a orchiectomy or organ preserving surgery along with 
monitoring of tumor marker levels should be the first treatment for all testicular tumors. Organ 
conserving surgery can be done in synchronous, metachronous or bilateral tumors. This should 
be followed by chemotherapy.(29) 
Testicular germ cell tumors had a cure rate of about 70% with stage I disease and surgery alone. 
In patients where serological markers are found elevated a wait and watch policy can be adhered 
to. In cases where the tumor recurs chemotherapy may not be able to give a survival advantage 
and cure rates as for stage I tumors. Schlatter et al concluded that children with stage I testicular 
germ cell tumors had an excellent outcome when treated with surgery alone. This was 
comparable to other studies which have been conducted.(30) 
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Children with malignant gonadal GCT have been found to have a higher overall and event free 
survival as compared to other sites. 85% of children studied by Wang et al had germ cell tumor 
of the testis. Only 33.3% were yolk sac tumors. Of the 59 patients available for follow up, only 
one had recurrence of disease which progressed to metastasis. This suggests that prepubertal 
testicular tumors are mostly benign and have an excellent prognosis.(31) 
 
Ovarian GCTs 
Ovarian germ cell tumors are more common than testicular germ cell tumors. These present 
mainly in adolescent girls. The usual presentation is of abdominal distention, pain or a mass. 
They may present occasionally with acute abdomen which may be a sign of ovarian torsion. 
Some children will have a workup with ultrasound and tumor markers like AFP and HCG, 
whereas others who present with an acute abdomen may have a laparotomy which then 
diagnoses a germ cell tumor on subsequent biopsy(4). 
Germ cell tumors have been found in 58% of primary ovarian tumors, in a study conducted in 
353 children. These tumors are more likely to be malignant (malignant teratoma, embryonal 
carcinoma, or dysgerminoma) than those in older patients.(32) 
Several studies have shown that a large proportion of these tumors are stage III or IV. The 
treatment given is a combination of chemotherapy and surgery. Outcome and results have been 
excellent with 93%- 97% overall survival for all stages as compared to previous studies.(32) 
In a study at the University of Texas MD Anderson Cancer centre, malignant ovarian GCTs were 
treated with upfront surgery followed by chemotherapy with BEP protocol. It was found that a 
majority of these were dysgerminomas. 95% of these patients were in remission. (33) 
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Tangir et al studied the reproductive function after fertility preserving surgery and chemotherapy 
in malignant ovarian germ cell tumors. Fertility preserving surgery involved excising the 
affected ovary and preserving the contralateral ovary and uterus and tube. Of the 86 women 
followed up, 38 had attempted conception. It was found that 76% of these women  followed up 
had 1 conception after completing treatment.(34) 
 
Abdominal and Retroperitoneal GCTs 
Germ cell tumors of the retroperitoneum can grow to a very large size before they are detected. 
They are detected by a parent accidentally while bathing a child, or when the child has some 
trauma. A good number of these are benign teratomas. This poses a problem as these tumors can 
be abutting major vessels, encasing them or splaying them. Chemotherapy cannot be used to 
shrink these tumors as these will not respond. AFP and βHCG should be obtained. Confirmation 
of the diagnosis is by radiological evaluation, and biopsies to rule out malignancy. In tumors 
which have malignant components chemotherapy can be used to reduce the tumor size so that 
these can be resected.(1) 
Multiple studies have shown abdominal and retroperitoneal tumors to be rare. Malignancy in 
these tumors is even rarer. The outcome for children with malignant abdominal and 
retroperitoneal tumors was measured in a study of 57 children by Brodeur et al. They found that 
stage was the most important factor in determining survival. These children with advanced stages 
had metastasis to the lungs bone and brain. Radiation was seen to improve survival in children 
who had non-disseminated GCTs.(35) 
Malignancy is observed in 15% of these cases. The mortality for retroperitoneal GCTs was 80% 
before the advent of platinum based chemotherapy. Billmire et al studied 317 children over a 6 
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year period of which 26 had malignant retroperitoneal tumors. Most of these children were girls, 
and despite malignant pathology the outcome was excellent following surgery and 
chemotherapy.(36) 
 
Germ Cell tumors of the Mediastinum 
Germ cell tumors of the mediastinum are rarely encountered. These tumors form a part of the 
spectrum of nongonadal germ cell tumors. The estimated occurrence is said to be 25% among 
nongonadal germ cell tumors in children according to some studies. Among these benign tumors 
teratomas have been found to be the commonest. The malignant germ cell tumors resemble 
testicular tumors in adults. However the occurrence of malignancy in germ cell tumors of the 
mediastinum is found to be rare in children.  
The following is a clinical staging used in Mediastinal Germ cell tumors. Stage I is well 
circumscribed tumors with or without focal adhesions to the pleura or pericardium, Stage II is 
tumor confined to mediastinum with macroscopic or microscopic evidence of infiltration into 
adjacent structures, Stage III is tumor with metastasis into adjacent intrathoracic organs (Stage 
III A) and metastasis into extrathoracic organs (Stage IIIB).(4)  
In a large study of primary mediastinal germ ell tumors Moran and Suster found that teratomas 
were most common. However they found that most of these were immature. They also found that 
among the malignant germ cell tumors, yolk sac tumors were the commonest.(37) 
In children mediastinal germ cell tumors can be diagnosed by radiology and tumor markers like 
AFP and βHCG. Teratoma is  the most likely diagnosis in neonates with large mediastinal 
tumors. However malignancy does occur rarely in adolescents. Surgical resection is the mainstay 
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in the management of teratomas. Surgery along with chemotherapy is the treatment of choice in 
malignant GCT’s of the mediastinum.(38) 
 
Tumors at miscellaneous sites 
Germ cell tumors have been diagnosed in the genitalia, the neck, and the stomach. Genital 
tumors arise primarily from the vagina. A majority of these tumors were malignant and had a 
very dismal prognosis. These present with bleeding per vagina, pelvic mass or urinary 
obstruction. This could be sometimes confused with botryoides type of embryonal 
rhabdomyosarcoma. Surgical extirpation was the only treatment available despite which the 
survival rates were low. The introduction of Platinum based chemotherapy has allowed vaginal 
preservation and survival of more than 80% for these girls.(2,4)  
The cervical and facial teratomas present in the neonatal period and most are either mature or 
immature teratomas. The usual presentation is airway obstruction. Giant tumors may cause 
hydrops which can cause fetal death. The Ex-utero Intrapartum Treatment (EXIT)  procedure can 
be performed for those without hydrops.(1,4) 
 
Survival and Prognosis of Malignant GCTs 
Most studies have shown an excellent survival in resectable teratomas. However teratomas of the 
mediastinum and retroperitoneum which are unresectable may cause respiratory or cardiac 
compromise and may lead to the demise in such children. 
The introduction of platinum based chemotherapy for the treatment of malignant GCT’s has 
significantly improved survival in children. Low stage tumors of the gonads have almost 100% 
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survival. Stage III and IV gonadal tumors have a 95% survival. Low stage extragonadal tumors 
have survival of 90%, whereas Stage III and IV tumors have survival rates of 75%.(2) 
Gastric teratomas in neonates have the best prognosis. Antenatally detected teratomas have been 
found to have mortality rates 3 times higher as compared to those diagnosed postnatally. Among 
the malignant GCT’s patients with Yolk sac tumors and gonadoblastoma were found to have a 
much better outcome than neonates with choriocarcinoma.  Choriocarcinoma has a survival rate 
as low as 12%. Platinum based chemotherapy has improved survival in neonates and infants with 
malignant GCT’s.(39) 
Children with testicular tumors were found to have event free survival (EFS) rates of 85% for 
stage I; for those who developed a recurrence there was a survival of 100% with salvage 
chemotherapy. For stage II disease it was found to be 100% 6 year EFS. The 6 year EFS for boys 
with stage III disease was 100% and 94% for stage IV disease. (8) 
Malignant ovarian GCT’s have an excellent outcome in children. Billmire et al found six year 
survival rates of 95% for stage I, 93% for stage II, 98% for stage III and 93% for stage IV tumors 
where the treatment protocol was followed completely.(18) 
The following table shows the event free survival(EFS) and survival in ovarian GCT.(18) 
Stage No 6 Yr EFS% 6 yr survival% 
I 41 95 95.1 
II 16 87.5 93.8 
III 58 96.6 97.3 
IV 16 86.7 93.3 
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The COG/CCG intergroup study found the 4 year event free survival for malignant 
sacrococcygeal tumors was 84+ 6%. They found 4 year overall survival rate of 90+ 4%. 
 The prognosis of malignant testicular GCT’s is the best.  The overall survival for malignant 
sacrococcygeal tumors has been found to be around 60% in some studies.(4,39) 
The overall outcome was found to be excellent in children with abdominal or retroperitoneal 
tumors. The POG/CCG study found a 6 year EFS of 82.8+ 10.9%, and an overall survival of 
87.6+9.3%.  Before the advent of platinum based chemotherapy this group had a mortality of 
more than 80%.(4) 
 The survival in children with mediastinal tumors was found to be 71+10%. Mortality was seen 
in children who were over 15 years of age. Yolk sac tumor was found to have a good response to 
treatment. 
The survival of children with tumors at various sites like the genitalia and the cervicofacial 
region depends on presentation. The tumors of the genitalia have a survival of around 90% 
according to the COG/CCG study. The tumors of the cervicofacial region are associated with 
fetal hydrops or with airway obstruction. Although benign the mortality in these tumors is high 
when associated with hydrops or airway obstruction. (1,2,4) 
 
Special Terminology 
Fetus in fetu has been thought to be a highly organized teratoma. Some people argue that it is 
distinct from a teratoma because of the degree of differentiation and the presence of the axial 
skeleton. Willis concluded that this was due to the incorporation of a diamniotic monozygotic 
twin into the body of its partner. Others argue that although placental findings are in favour of 
twin origin, teratomatous recurrence shows a link in development of fetus in fetu and teratoma. 
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Cases have been reported of coexisting fetus in fetu and malignant teratoma. According to the 
WHO classification fetus in fetu is regarded as a mature teratoma. (6,40) 
Struma ovarii is the presence of thyroid tissue in a mature teratoma. Malignant transformation 
can occur rarely, with metastatic disease reported in approximately 20 cases. These tumors can 
be treated like their thyroid counterparts with cytoreductive surgery and radioiodine ablation.(41) 
Growing Teratoma Syndrome  is defined as an increase in tumour size during or after 
chemotherapy for germ cell tumour (GCT), and only mature teratoma at histological analysis of 
the resected tumour specimen.(2,42) 
Malignant transformation has been reported frequently in benign and immature teratoma. These 
tumors which recur and have malignant transformation are very aggressive. The frequency of 
malignant transformation mandates long term follow up in all teratomas especially the ones 
which have immature elements. Large tumors with immature elements have a high chance of 
malignant transformation. Malignant transformation has been seen in cervical teratomas, 
mediastinal, retroperitoneal, gonadal and sacrococcygeal teratomas.(43) 
 
Recent Advances 
Various advances have been made in the treatment of germ cell tumors whether it concerns 
diagnosis, treatment which may be single modality or multidisciplinary. All these have improved 
the survival in children with germ cell tumor. 
 Germ cell tumors can be diagnosed antenatally. This has been made possible by the advent of 
high resolution ultrasound. In-utero diagnosis is made possible for sacrococcygeal teratomas. 
Most of these tumors are benign but some may have a yolk sac tumor component.  
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The mortality from fetal sacrococcygeal teratomas is very high. This occurs in fetuses which 
develop hydrops or if the tumor is diagnosed before 30 weeks of gestation. The ex-utero intra-
partum treatment (EXIT)  procedure is used to debulk this tumor to prevent the arterio-venous 
shunt which occurs due to the bulk of these tumors.(6) 
The introduction of various imaging techniques for diagnosis of germ cell tumors can describe 
the area of the tumor, any local extension and distant metastasis. Computed Tomography 
scan(CT) and Magnetic Resonance Imaging (MRI) are now regularly used to determine the 
extent of tumor. Three Dimensional imaging has now come into vogue with the advances in MRI 
and CT imaging. 3-D imaging is used to map the tumor its extent blood supply and 
treatment.(13,44,45) 
The tumor markers AFP and βHCG are now used not only to diagnose malignant germ cell 
tumors but also the response to therapy. Persistently elevated level of markers suggests non 
response to therapy. Steady decline with normal levels of markers suggests complete response. 
Elevation after an initial fall suggests resurgence or incomplete response to therapy.(1,2,4) 
Introduction of platinum based chemotherapy has improved survival in children with malignant 
germ cell tumors. The Children’s Cancer Group (CCG) and the Pediatric Oncology Group 
(POG) have established and improved on protocols which have been formulated in the last 
decade which have helped improve survival to very significant level. The introduction of these 
protocols has increased survival to above 95% for most stages of malignant GCT’s compared to 
a survival of 50-60% previously. The survival of children with tumors especially of the genitalia 
was dismal and rates were as low as 30% in some studies.(1,14,26,33,35,45–47) 
The introduction of Flouro-Deoxyglucose Positron Emission Tomography has added a new 
dimension to the management of malignant germ cell tumors. The use of PET has not been fully 
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realized in the treatment of germ cell tumors. PET scans have been found to be superior to CT 
for residual tumors and also for response to therapy. The limiting factors for its use is the 
availability and cost.(48) 
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MATERIALS AND METHODS 
 
Study Design 
This is a retrospective study of all children below 16 years of age who were diagnosed to have 
extracranial germ cell tumors (GCTs) in the department of Paediatric Surgery, Christian Medical 
College and Hospital between January 2003 and December 2012. 
 
Patients 
107 children, below the age of 16 years, who were diagnosed to have extracranial germ cell 
tumors, between January 2003 to December 2012, were included in this study.  
 
Data Collection 
 All the patients or their relatives were informed by phone or by mail by the investigator, and 
enquiries made into their present status and outcome. For all patients who  followed up a consent 
was obtained. A proforma was filled by the investigator.  The operative records, investigations 
and follow up records were collected from the hospital database and records and reviewed and 
also included in the proforma.  This data was tabulated into Microsoft excel worksheet and then 
analyzed as such using demographic, clinical, biochemical and radiological parameters.  
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Data Analysis 
Descriptive statistics were reported using Mean±SD/ Median (IQR) for continuous variables. 
Categorical variables were reported using Frequency and Percentage. Chisquare /Fisher’s exact 
test and two independent Sample t test/ Mann Whitney’s U test were used to assess the variables. 
Binary Logistic Regression was used to look at the risk factors associated with mortality. Overall 
Survival (OAS) and Event Free Survival (EFS) were estimated using Kaplan Meier survival 
curves. Log rank statistics was used to assess the significance of the factors associated with OAS 
and EFS. P value <0.05 was considered to be statistically significant. Analysis was done using 
SPSS 16.0. 
 
Exclusion Criterion 
Children who had intracranial germ cell tumors 
 
 
 
 
 
 
 
 
 
 
 
 Christian Medical College had a total of 1532840 patients in OPD in 2011 of which 
approximately 66040 were seen in 
paediatric oncology had 8500 patients. Approximately 100
treatment of paediatric solid tumors every year, of which 8
All children below the age of 16 
(GCTs) from January 2003 to December 2012 were recruited into this study.
A total of 107 children were diagnosed to have extra cranial GCT from January 2003 to 
December 2012 who presented to the department of Paediatric surgery. 
 The age ranged from a day old neonate to 14 years. 29 children were less than one year of age, 
31 were between 1 and 5 years. 22 children between 5 and 10 years and 25 were more than 10 
years of age at the time of diagnosis. 38 of these children were male and 69 were female.
Figure 1: Age Distribution of Germ Cell Tumors
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Table 1: Distribution of GCTs According to Site and Age. 
Site Age 0-1year 1-5 years 5-10years >10years Total 
Testicular 4 7 1 5 17 
Ovarian 0 4 13 13 30 
Sacrococcygeal 13 7 5 0 25 
Retroperitoneal 5 9 1 1 16 
Abdominal 3 2 0 2 7 
Thoracoabdominal 1 0 0 0 1 
Mediastinal 0 1 1 3 5 
Miscellaneous 3 1 1 1 6 
Total 29 31 22 25 107 
 
47 (44%) children had gonadal GCT comprising the largest group in this study. 25 (23%) 
children had sacrococcygeal tumors, 16 (15%) had retroperitoneal, 7 (6%) had intra-abdominal 
tumors, 5 (5%) had mediastinal, 1 (1%) had thoracoabdominal and 6 (6%) had tumors at 
miscellaneous sites like the neck, vagina, bladder etc. 
 
 
 
 
 
 Figure 2: Distribution of GCTs according to site
 
 
Figure 3: Distribution of GCTs
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 49 of the 107 children had malignant tumors, 49 had benign tumors and 9 had immature 
teratomas. 13 of the 17 children with testicular tumo
with ovarian tumors had malignancy, and 8
malignant components. Malignancy was seen in 3
the rate of malignancy among the children with abdominal tumors was 1
thoracoabdominal tumor was diagnosed to have a malignant tumor. All the mediastinal tumors 
were benign. 4 of the 6 children with tumors at miscellaneous sites had malignancy.
 
Figure 4: Distribution of GCTs
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Table 2: Distribution of GCTs according to Histology 
Malignant Benign Immature Total 
Testicular 13 3 1 17 
Ovarian 19 9 2 30 
Sacrococcygeal 8 15 2 25 
Retroperitoneal 3 11 2 16 
Abdominal 1 4 2 7 
Thoracoabdominal 1 0 0 1 
Mediastinal 0 5 0 5 
Misc 4 2 0 6 
Total 49 49 9 107 
 
Histopathology Pictures of GCTs 
Figure 5:  Mature Teratoma 
 
 
 
 Fig 6:  Yolk Sac tumor 
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Figure 7: Dysgerminoma 
 
Fig 9: Embryonal Carcinoma 
Figure 8: Immature Teratoma 
 
Figure 10: Yolk Sac Tumor Testis
 
 
All Children with malignant GCTs had an elevated AFP. In some ovarian GCTs β HCG was also 
elevated. The elevation ranged from a few hundreds to a few lakh IU/ml (range300-1000000 
IU/ml). The AFP levels decreased consistently with treatment in the malignant GCT. This will be 
discussed in detail in the specific tumor sections. 
 The overall survival was 95% for all GCT’s. The median survival was 50 months. Median 
survival among females was 51 months and for males 
children with benign GCT was 58 months, for immature GCT was 48 months and for malig
GCT was 44 months (p=0.020).
Figure 11: Cumulative Survival in GCT
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was 44 months. The median survival for 
 Overall survival for malignant GCT was 85.2%
s
nant 
 Figure 12: Survival against Histology
Event free survival in all GCTs was 85%. The event free survival in females was 85% and i
males was 84%. The event free 
was 87.4% and for benign tumors was 100%
Figure 13: Event Free Survival in GCTs
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 in GCTs
survival in malignant GCT was 75.9%, in immature teratomas 
. 
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 Testicular Germ Cell Tumors
Boys with testicular tumors formed 17% of the patients 
Table 3: Age distribution of children with Testicular Tumors
Age 0-1 years 1-5years
Number(n) 4 7 
 
16 (94%) of the 17 boys  who presented with a testicular tumors had a mass of the side of the 
scrotum which was enlarging. 1 child who had an undescended testis
pain and vomiting and was found to have an intra
This tumor was malignant. 1 child presented with abdominal distention in assoc
enlarging scrotal mass. 
Figure 14: Testicular Germ Cell Tumor in a 2 year old boy
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studied with GCT.  
 
 5-10years >10years Total 
1 5 17 
, presented with abdominal 
-abdominal testis which had undergone torsion. 
 
iation with an 
 Of the 17 boys, 13 (76.5%) had malignant GCT 3
teratoma.  
Figure 15: Distribution of Testicular GCT according t
Table 4: Distribution according to Histology in Testicular GCT
Histology Benign Yolk 
Sac 
Tumor 
Number 3 
(17.6%) 
10 
(58.8%)
 
3
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 had benign teratomas and 1 had an immature 
o histology 
 
Embryonal 
Carcinoma 
Mixed 
Malignant 
Germ Cell 
Tumor 
Non 
Seminomatous 
GCT 
 
1 (5.8%) 1 (5.8%) 1 (5.8%) 
13
1
Malignant
Benign
Immature Teratoma
 
Immature 
Teratoma 
1 (5.8%) 
 Treatment given was a high orchiectomy followed by 6 cycles of JEB (Carboplatin, Etoposide 
and Bleomycin) in 12 (85%) children. This was followed by IVAD in 1 and IVeP in one child.
child had abandonment of treatment as there was extensive met
Overall survival was 85.7% for children with
71.4%. 1 child had abandonment of treatment as there was widespread metastatic disease. Follow 
up ranged from 12-108 months. Median survival was
showed adequate growth for age and had no follow up problems which included renal and 
respiratory function. 
Figure 16: Overall Survival in 
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astatic disease. 
 malignant testicular GCT. Event free survival was 
 49 months. All the children who survived 
Malignant Testicular GCT 
 1 
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Ovarian Germ Cell Tumors 
30 girls presented with ovarian germ cell tumors. These constituted 26.4% of all children with 
germ cell tumors. The most common presenting feature was pain which was seen in 66.6% 
(n=20) patients. This was followed by a mass in association or in isolation in 50% (n=15) 
patients. 13% (n=4) had associated vomiting. 1 child presented with associated fever and loss of 
weight, 1 with abdominal distention and 1 with ascites. 
Screening radiology showed the size of the mass the extent, but it was difficult to tell the 
originating side of the ovarian mass due to the size of some of these tumors. The masses ranged 
from 4cm by 3 cm to 19cm by 10 cm and in some cases occupied most of the peritoneal cavity. 
Follow up screening radiology showed residual masses post chemotherapy in these children. The 
size of these masses had become half to one third of the original in a majority of these children. 
Operative findings were consistent with the radiological findings.  A unique feature in 3 children 
was that they had torsion with gangrene of the ovary. 
18 (60%) of these girls had malignant germ cell tumors and 12 (40%) had benign teratomas of 
the ovary. The AFP was elevated in all the children with malignant GCT. AFP ranged between 
88- >1000000 IU/ml. βHCG was raised in 10 patients. Range was from 27.8-196900 IU/ml.  
The diagnosis was based on tumor markers and radiological findings in most. 15 (83%) of the 18 
children were treated based on tumor markers. 3(16%) were treated for malignancy following a 
laparotomy for acute abdomen in which torsion of ovarian mass was found and subsequent 
biopsy exhibited a malignant GCT.  
 
 
 
 Figure 17: Distribution of Ovarian GCT according to Histology
 YST- Yolk Sac tumor, EC- Embryonal Carcinoma, DG
NSGCT- Non seminomatous GCT, MT
malignant GCT  not otherwise specified. 
2(13.3%) of the children with malignant disease
(Cisplatinum, Etoposide and Bleomycin) and 16 (86.6%) were treated by the JEB protocol
children who received preoperative chemotherapy were treated with 4
followed by 2-4 cycles of the same chemotherapy post operatively. 1 child had a recurrence after 
primary treatment and was given VeI
primary chemotherapy and surgery.
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Table 5: Trends of AFP levels once therapy was initiated and at follow up 
AFP (IU/ml) At Diagnosis Post 
Chemotherapy 
Post 
Chemo/Surgery 
At 
completion/follo
w up 
0-50 6 8 14 17 
50-100 1 0 0 0 
100-1000 1 5 2 0 
1000-10000 2 1 1 0 
10000-100000 6 2 0 0 
>100000 2 1 0 0 
 
The children with ovarian GCT had a good overall survival in this study. 28 of the 30 girls 
survived. 2 children had abandonment of treatment. Both had recurrent metastatic disease which 
was non-responsive to chemotherapy. 
Follow up ranged from 2 months to 120 months with a median survival of 44 months. Overall 
survival (OS) in those with malignant ovarian GCT was 90% and the event free survival (EFS) 
was 85%. The children who have survived have shown an adequate growth pattern. A number of 
them have attained menarche. 1 of the patients is married and has 2 children, 5 years after 
completion of treatment. 1 child has ovarian failure, has failed to attain menarche, and has not 
developed secondary sexual characters.  
 
 
 Figure 18: Overall Survival in M
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Sacrococcygeal Teratoma (SCT) 
There were 25 children who presented with sacrococcygeal teratoma constituting 23% of 
children in this study. 7 (28%) of these children were male and 18 (72%) were female. 4 (16%) 
children presented at birth. 8 (32%) presented by 1 year of age. 12 (48%) presented between 1 
year to 10 years of age.  
Figure 19: A New Born with Sacrococcygeal Teratoma (SCT) 
 
 
 
 
 Table 6: Age distribution in Sacrococcygeal Teratoma
Age (years) 
0-1 
1-5 
5-10 
>10 
Total 
 
Figure 20: Gender Distribution of SCT
 
14 (56%) children had benign tumors, 8 (32%) had malignant components a
immature elements. Of the children with malignancy 5(62.5%) were females and 3(37.5%) were 
males. 
72%
44 
 (SCT)  
Number(n) Percentage (%)
8 32 
12 48 
4 16 
1 4 
25 100 
 
28%
Gender 
 
 
nd 3(12%) had 
Male
Female
 Figure 21: Percentage Distribution according to Histology in SCT
24 (96%) of the children with SCT 
no visible mass. Associated features at 
sinuses in 1 child. One child had been operated at birth but the mass had recurred after 7 months, 
1 child had a sudden increase in the size of the m
presentation, 1 child had presented with a neurogenic bladder and 1 with weakness of the rectal 
sphincter and was incontinent to stools.
Table 7: Associated Symptoms in SCT
Symptom Pain 
Number 1 
 
56%
12%
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 presented with a sacrococcygeal mass.  1 child 
presentation were paraparesis in 1 child
ass, and 1 had a biopsy of the mass before 
 
 
Paraparesis Sinuses Neurogenic  
bowel and 
bladder 
1 1 2 
32%
Malignant
Benign
Immature
 
had pain with 
, and multiple 
Sudden 
increase in 
size of mass 
1 
 Table 8: Distribution According to Altman Classification of SCT
Altman Type Number
I 10 
II 7 
III 6 
IV 2 
 
Figure 22: CT Scan of an Altman Type III SCT
The tumor size ranged from 1.4 cm by 4 cm to as large as 20 cm by 15 cm in size.
All 8 (100%) children with malignant SCT had elevated AFP. AFP levels ranged between 816 
IU/ml to 140800 IU/ml. This value decr
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 Percentage of total Percentage 
40% 0% 
28% 14% 
24% 83% 
8% 100% 
 
eased consistently with treatment including surgery and 
Malignant 
 
 
 chemotherapy. 2 (66%) of the 3 patients with immature teratomas had raised AFP. R
3.14IU/ml to 30000IU/ml. 
Follow up ranged from 12 months to 120 months. 2 of the children with SCT died. 1 chi
one year after diagnosis, the other died 4 years after completion of treatment of unrelated causes. 
The overall survival was 92% and EFS was 80%. 
60%. 
Some of these children have residual problems. 3 (12%) ch
child has weakness of the rectal sphincter, and 1 child has developed a hemoglobinopathy and is 
on treatment.  
Figure 23: Survival in Malignant
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Retroperitoneal GCT 
16 children of the 107 had retroperitoneal teratomas. This constituted 15% of the total study 
population. 8 (50%) were girls and 8 (50%) were boys. Age at presentation ranged from 2 
months to 14 years. Mean age was 32 months.  
Table 9: Age Distribution of Retroperitoneal GCT 
Age(years) 0-1 1-5 5-10 >10 Total 
Number 5 9 1 1 17 
 
Table10: Distribution of Symptoms in Retroperitoneal GCT 
Symptom Mass Percentage 
Number 12 75% 
Abdominal Distension 9 53% 
Pain 4 25% 
Vomiting 1 6% 
Paraparesis 1 6% 
 
Radiological screening by way of CT scan or Ultrasound of the abdomen was done for these 
children. The tumor size ranged from 6cm to 15 cm diameter. 2 (12.5%) of these tumors were 
present on the right of the midline, 9 (56.25%) were midline tumors, and 5 (31.25%) were 
present on the left of the midline. 2 were in relation to the left kidney and 2 in the right 
suprarenal region. 1 child had metastasis to the liver. 
 
 
 Figure 24: Pretreatment CT scan in a Malignant
 
Figure 25: Post Chemotherapy
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 Retroperitoneal GCT  
 CT Scan for the same patient 
 
 11(68.8%) children were diagnosed to have benign lesions and 3 (18.7%) had malignant lesions. 
2(12.5%) child had an immature teratoma. AFP was elevated in the children with malignant 
neoplasm. It ranged from 139 IU/ml to >30,000 IU/m
3 of the children with malignant neoplasms were given 4 cycles of JEB chemotherapy, 1 child
with immature teratoma was given four cycles of 
pattern with chemotherapy. There was a significant reduction in size of the tumor following 
chemotherapy in all the children with malignant GCT. The size ranged from 2 cm to 7cm in 
largest diameter as compared to 6cm to 15 cm pre chemotherapy. 
Figure 26: Distribution According to Histology in Retroperitoneal GCT
Surgery was performed as an adjunct 
children with benign disease. 17 of the children had complete excision of tumor. Surgery had to 
be abandoned in the child with the immature teratoma as the portal vein and the superior 
mesenteric artery, the aorta and the IVC were all traversing 
69%
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JEB.  Values of AFP followed a decreasing 
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Follow up ranged from 12 months to 108 months. Overall survival was 93.7%. The survival for 
children with malignant GCT was 100%. Median survival was 48 months. Event free survival 
was 80%. 1 child with an immature teratoma had abandonment of treatment as the tumor was 
unresectable and did not respond to chemotherapy. This child expired 11 months later. 
Abdominal GCT 
There were 7 children with intra-abdominal GCT. This constituted 6.5% of the study population. 
3 of these were males and 4 were females. 3 had gastric teratomas, 1 had a teratoma anterior 
abdominal wall and 1 had a teratoma of the liver and 2 had intra-abdominal teratoma.  
Table 11: Distribution of Abdominal GCT According Site   
Site Gastric Abdominal Wall Liver Intra-
abdominal 
Number 3 1 1 2 
 
5 (72%) of these children presented with mass abdomen. 1 (14%) child had an exomphalos, and 
1 (14%) child had pain abdomen. 
On radiological screening the size of the tumor ranged from 6cm to 15 cm in greatest dimension. 
6 of these children underwent laparotomy and excision of these tumors. 4 of these lesions were 
diagnosed to be benign on biopsy. 1 child had an immature teratoma of the lesser curve of the 
stomach. 1 child had a needle biopsy, which showed malignant histology. The child had 
neoadjuvant JEB chemotherapy. 
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Table 12: Distribution of Abdominal GCT according to Histology 
Histology Malignant Benign Immature Teratoma 
Number 1 4 2 
 
One child with the malignant tumor had elevated AFP levels which did not decrease with 
chemotherapy. The child underwent 2 cycles of chemotherapy after which her treatment was 
abandoned. She eventually died within a few days. 
One child with an immature teratoma also underwent preoperative chemotherapy and excision of 
tumor. 
Follow up ranged from 15-120 months. 6 of the 7 children survived making the overall survival 
85.8%. Median survival was 42 months. Event free survival was 80%. 1 child had abandonment 
of treatment and died 2 months later. 1 child had a gastro-esophageal reflux which was treated by 
medical measures. 
 
Mediastinal GCT 
5 children had thoracic teratomas constituting 4.7% of the study population. The age of these 
children at diagnosis ranged from 3 years to 14 years. Median age was 11 years. 4 (80%) were 
girls and 1(20%) was a boy. 
These children presented with varied symptoms. 1 had pain in the right chest, 1 had respiratory 
distress, 1 had fever and loss of appetite, and 1 child had hemoptysis. 
  
Table 13: Distribution of Symptoms in Thoracic GC
Symptom Pain Chest 
Number 1 
 
Radiological screening revealed 4 of these masses to be located in the anterior mediastinum, and 
1 extending to the thoracic aorta from the thymus. The masses
greatest diameter. 
Figure 27: CT scan of a Child with Mediastinal GCT
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The tumor markers were normal in all these children. Operative approach was through a 
thoracotomy and excision of the tumor in 4 children. 1 child had a median sternotomy. The 
operative findings showed large tumors containing hair, cheesy material in all these tumors. In 
one child the tumor was extending to the thoracic aorta. 
Biopsy was consistent with mature teratoma in all these children. All of these children survived 
the treatment. Median survival was 54 months. One child has concomitant factor VII deficiency. 
 
Thoracoabdominal GCT 
One child was diagnosed with a thoracoabdominal teratoma. He was a male and 12 months at the 
time of diagnosis. 
He presented with breathing difficult. X-ray showed a radiopaque mass in the right hemithorax. 
Due to the breathing difficulty and mass a CT was done which showed a 12 cm by 10 cm 
heterogenous mass in the posterior mediastinum which was extending into the abdomen. 
To relieve him of his symptoms a right thoracotomy and excision of the thoracic part of the mass 
was done. Biopsy revealed a yolk sac tumor. He was given 2 cycles of JEB chemotherapy which 
was followed by laparotomy and excision of abdominal part of the mass. 
4 cycles of chemotherapy was given post operatively. He is alive and well. His growth is 
adequate for age. He has been on follow up for 24 months.  
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GCT at Miscellaneous Sites 
6 children had tumors at miscellaneous sites constituting 5.6% of this study population. 5(83%) 
of these were female and 1 (17%) was male. Age ranged from 2 months to 13 years.  
These children had varied presentations. 2 children presented with a mass on the right side of the 
neck.1 of these children had an associated mass right thigh.  2 children presented with bleeding 
per vagina at 7 months and 10months of age. 1 child had a mass in the right gluteal region with 
an associated hypospadias. 1 child presented with chest pain. 
Table 14: Site of miscellaneous tumors 
Site Neck Vagina Gluteal Lung 
Number 2 2 1 1 
 
The AFP was raised in 4 children ranging from 2410 IU/ml to 58000 IU/ml. All 4 were 
diagnosed to have malignant germ cell tumors. The size of the tumors of the neck ranged from 
10cm to 20 cm in greatest diameter. The gluteal mass was 3 cm and the vaginal mass ranged 
from 3cm to 4 cm in greatest dimension. 
 
 
 
 
 
 Figure 28: Distribution according to histology in Miscellaneous Site GCT
3 of these children were given neoadjuvant chemotherapy. 1 of these was a child with malignan
neck GCT and one a vaginal GCT and 1 with lung GCT. 3 children had no chemotherapy but 
primary excision of the mass. 
Follow up ranged from 12-120 months. The child with the metastatic germ cell tumor had 
abandonment of treatment. 5 children survived. The
was 71 months.  The event free survival also is 80%. The child with the gluteal teratoma had 
right lower limb weakness and is on physiotherapy.
 
 
 
 
33%
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 overall survival was 80%. Median survival 
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Figure 29: X-ray of an Infant with Cervical GCT
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Figure 30: PET CT in a Child with Malignant Testicular GCT showing no residual disease 
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Discussion 
Extracranial Germ cell tumors (GCTs) are rare tumors which occur in children and adolescents. 
We found an incidence of 0.1% among all paediatric malignancy seen in CMC Vellore and 8-
10% of all  Paediatric solid tumors treated here. Rescorla reported an incidence of  1-3% of 
childhood tumors, Khanna et al and  Sarin and Bhatnagar in their review, reported an incidence 
of 7-10% among solid tumors in childhood.(1,2,5–8)  
These tumors are commonly seen in females. Our study had a similar findings with 64% tumors 
diagnosed in female children with a female to male ratio of 1.8:1. A higher incidence among 
females has been reported in literature.(1,2,6,7)   
Tumors were almost equally distributed among 0-1year, 1-5 years, 5-10years, and 10-16 years 
with distribution being 27%, 29%, 21% and 23% respectively. Some series have reported a 
bimodal peak for age groups while others have reported a different age peak for different sites. 
(1,2,6,7)
 
Gonadal GCTs formed the largest group in our study with 44% (n=47) distribution. The ovary 
was the commonest site involved with 28% (n=30) children forming this group. This contrasts 
earlier series by Billmire and Grosfeld(3), and Isaacs(6), Abubakar et al(22) which have reported 
sacrococcygeal teratomas to be the commonest. However some series have shown gonadal GCTs 
to predominate (7,39,47). Some series report a higher incidence of non gonadal GCTs in early 
childhood and predominance of gonadal GCTs during adolescence (12,49,50). 
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Benign GCTs formed a majority in our series with 54% (n=58) being mature or immature 
teratomas. 46% (n=49) were malignant.  Khanna et al reported a 34.1% incidence of malignancy, 
Sarin and Bhatnagar 13-17%, Schropp et al 21%, and Billmire and Grosfeld 28%. (3,7,8,51) 
Imaging and tumor markers were used to diagnose GCTs. The tumor markers were elevated in 
all malignant GCTs and in infants with benign teratomas. Tumor markers returned to normal 
levels once surgery was undertaken or chemotherapy was started. Tumor markers showed an 
increase in case of recurrence. A decrease in tumor markers was not seen  in case the tumor did 
not respond. Imaging in the form of ultrasound scan, CT scan, MRI and Pet were used to 
evaluate patients for diagnosis and response to treatment. CT scan and MRI were used in case of 
recurrence. Tumors which responded to neoadjuvant chemotherapy had a significant decrease in 
size and the reverse was true for tumors which did not respond. PET CT was used to delineate 
any residual disease or new foci of disease following completion of therapy. Several reports have 
emphasized the usefulness of imaging techniques and tumor markers in GCTs which are 
intrapelvic, abdominal, retroperitoneal and intrathoracic. (1,10,13,22,35,44,46,48,52,53)    
Chemotherapy in the form of Carboplatin, Etoposide and Bleomycin (JEB), or Cisplatinum, 
Etoposide and Bleomycin (PEB) were used to treat patients with malignant GCTs. Several series 
have shown very good outcomes for GCTs especially of the gonads.(1,4,8,19,46,49,54) 
Neoadjuvant chemotherapy was used in malignant ovarian GCTs based on tumor markers and 
imaging only. Response was seen by decrease in size of tumors and levels of tumor markers on 
follow up investigation. Following 2-4 cycles of chemotherapy, surgery was performed. This 
was followed by 2-4 cycles of JEB or PEB chemotherapy. Preoperative chemotherapy has been 
used in the MAKEI and MAHO protocols (5). Other series suggest upfront surgery followed by 
61 
 
chemotherapy for most extracranial malignant GCTs(33). Some series have reported usage of 
both preoperative and postoperative chemotherapy for malignant GCTs(20). 
Chemotherapy was also used in some children with immature teratomas in our series. Earlier 
studies propagated the use of chemotherapy for all children with immature teratomas citing a 
high chance of recurrence. This was based on treatment protocols which are still followed in 
adults(55). Earlier series have reported treatment with a combination of chemotherapy and 
radiotherapy in combination with surgery(56).Most studies now combine a complete excision 
followed by close follow up of all patients with immature teratoma(1,2,19,47).  
Radiotherapy has been used to treat the local area in non seminomatous germ cell tumors. This 
modality has not been used in our series.(4,35,46) 
The overall survival (OS) for all GCTs in our series was 95%. The median survival was 50 
months; 51 months among females and 44 months among males. The median survival for 
children with benign GCTs was 58 months for immature teratomas was 48 months and for 
malignant GCTs was 44 months (p=0.020). The overall survival in malignant GCTs was 85.2%. 
Most studies reviewed by us mention an OS of 70-95% for malignant GCTs depending on stage 
and site of disease. The low stage gonadal tumors have an excellent overall survival of 90-
100%.(1,8,18,19,25,35,44,49) 
The event free survival (EFS) in all GCTs in our study was 85%. The EFS in females was 85% 
and in males was 84%. The EFS for all malignant GCTs was 75.9%, for immature teratomas was 
87.4% and for benign tumors was 100%. There are different reports in literature which place 
EFS at 63-95% in malignant GCTs. EFS varies for different sites. This will be discussed in the 
individual tumor sites.(18,35,46,52) 
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Testicular tumors were present in 17% (n=17) patients in our series. This is the third largest 
group in our series. 64% (11/17), patients were below 5 years of age and malignancy was present 
in 76.5% (n=13) patients. Testicular GCTs were present in 10% of patients in the series report by 
Billmire and Grosfeld(3), 17% by Brodeur et al(35), as the third commonest by Khanna et al(7) and 
27% by Wollner et al(9) and 18% by Gobel et al(5).  Wang et al reported a 33.3% incidence of 
malignancy(31), 100% by Khanna et al,  and 22%-63% in other studies(1). Most authors talk about 
benign tumors predominating during early childhood and malignant tumors in adolescence(1,2,4).  
OS and EFS were 85% and 71% respectively. Most studies now report a 100% survival for stage 
I and II (30,57,58), and 93% for all stages(39). 
26.4% (n=30) children presented with ovarian GCTs with 60% (n=18) of the tumors having 
malignancy and 10% (n=3) presenting as acute abdomen with torsion. This was the largest group 
in our study. Ovarian GCTs have been found to be the commonest site with varied incidence of 
malignancy in several reports by Brodeur et al reporting ovarian tumors as 30% of their study(35), 
26% by Gobel et al(5), and 50% by Wollner et al. The ovary as the second most common site for 
GCTs has been seen in studies by Billmire et al(18), Khanna et al (7), and by Suita et al(39). A high 
incidence of malignancy in our study can be explained by CMC Vellore being a tertiary level 
institution and where the patients are referred for advanced management. 
The methods for diagnosis were imaging by way of USG scans, CT and MRI. Tumor markers in 
addition were used to substantiate the diagnosis. These methods are now commonly adopted for 
diagnosis of GCTs  in literature.(3,5,13,16,18,46,47) 
83% (n=15) of the children with malignant ovarian GCTs were treated on the basis of imaging 
and tumor markers without biopsy, using neoadjuvant chemotherapy followed by surgery and 
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adjuvant chemotherapy. This protocol has been followed by the MAKEI and MAHO studies(5) 
and also in the UKCCSG GCII trials (49) and has been mentioned by Sarin and Bhatnagar(8). The 
POG, CCG groups follow upfront surgery for either complete resection, staging and debulking 
followed by chemotherapy(3,16,18,33,46,54,59). 
The OS and EFS for malignant ovarian GCT was 90% and 85% respectively. Median survival 
was 44 months. With the newer protocols followed OS and EFS are in the range of 83%-95% 
and 93-95% respectively as reported in several studies for malignant ovarian GCT(4,5,16,18,47,59). 
1 of the subjects is married after completion of treatment for malignant ovarian GCT. She is the 
mother of 2 children. There are reports in literature of fertility after treatment for gonadal 
GCTs.(34) 
23% (n=25) patients in this series had Sacrococcygeal teratomas (SCT). 72% (n=18) were 
female and 28% (n=7) were male with a male to female ratio of 1:2.8. 16%(n=4) presented at 
birth, 32% (n=8) presented before 1 year of age and 48%(n=12) presented after 1 year of age. 
SCT is the most common tumor in most series reported in literature with comprising 50% of 
tumors of the series(1,3,5,6,60). 
40% (n=10) of SCT were Altman type 1. The incidence of malignancy in Altman Type II to type 
IV tumors increased exponentially with type IV having 100% malignant components. This is 
comparable to reports by Billmire(1),  Ashour and Ehlalaby (14)Altman(21), and Abubaker et al(22). 
The diagnosis and management were according to protocol. 1 child with malignant components 
on needle biopsy received neoadjuvant chemotherapy. All children with malignant components 
received chemotherapy following resection. OS and EFS in malignant SCT was 80% and 60% 
respectively. Recurrence was seen in 7 (28%) patients with SCT. A similar OS and EFS has been 
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reported in literature(1,3,5,6,19,23). High  recurrence rate of 20-55% has been reported in a study by 
De Backer et al(61). 
Retroperitoneal GCTs comprise 16% (n=16) of our study group. 8 were females and 8 were 
males. 68.8% (n=11) were benign. Retroperitoneal GCTs comprise 4-5% of case series reported 
in literature, and a majority are benign(3,5).The diagnosis and management were according to 
protocol. 1 child with immature teratoma underwent a laparotomy to resect the tumor which had 
to be abandoned as the tumor was unresectable. 2 cycles of JEB chemotherapy was tried and the 
child did not respond. The OS and the EFS for malignant tumors was 100% and 80% 
respectively. Similar reports are available in literature. (3,5,35) 
Abdominal GCTs comprised 6.5% (n=7) of our study population. 57% (4) were female and 
43%(n=3) were male. 1 of these tumors was malignant. 1 child with immature teratoma on 
biopsy was given neoadjuvant chemotherapy following which she underwent resection. The 
protocol followed for immature teratoma has been reported earlier(56). Some protocols follow the 
complete resection and close follow up of these tumors(1,5). The OS and EFS were 85.8% and 
80% respectively. Most series report similar incidence(1,5) 
Mediastinal tumors comprised 4.7% (n=5) of our study population. 80% (n=4) were females and 
all these tumors were benign. Treatment given was primary resection of these tumors. Most 
series report mediastinal tumors as being mostly benign with a small proportion being 
malignant(1,5). Among mediastinal GCTs 86% are reported to be benign by Billmire et al(45), and 
43% by Moran and Suster(37). 
70% of children with tumors of miscellaneous sites had malignancy. These included the neck, 
the lung, genitals and the bladder. A majority of these were females. Diagnosis was based on 
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imaging, tumor markers and biopsy. Chemotherapy was given in 4 children. OS and EFS was 
80% in malignant GCTs of miscellaneous sites.  Reports of similar findings and treatment are 
found in literature(1,2,7,62). One child with vaginal Yolk Sac tumor was given only chemotherapy 
and this child is well on a 4 year follow up.  
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Conclusions: 
Germ cell tumors are rare set of tumors. These occur at many sites. They can be benign in the 
form a mature teratoma, immature teratomas or malignant from the seminomas to the embryonal 
carcinoma. 
The commonest Germ cell tumors are the Sacrococcygeal teratomas, although in our series 
ovarian germ cell tumors were more common (28% against 23%). 
Germ cell tumors occur more commonly in females (64% in our series). 
There is a variable age range from infancy to adolescence. Most occur in early childhood. (56% 
were between 0 to 5 years in our series). 
Benign tumors predominate (54% in our series). 
Malignant tumors are diagnosed by tumor markers imaging and biopsy. Treatment for malignant 
tumors is multimodality with neoadjuvant chemotherapy, surgery and adjuvant chemotherapy.  
Chemotherapy using JEB (Carboplatin, Etoposide and Bleomycin) is highly effective in down 
staging disease and decreasing the size of tumors thus making surgery easier. 
Neoadjuvant chemotherapy without biopsy can be used to treat malignant ovarian GCTs as this 
helps in reducing tumor burden and shrinking the tumor. 
Long term survival is possible in malignant germ cell tumors after the introduction of 
Cisplatinum based chemotherapy. 
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Recurrence is a possibility in cases of immature teratomas or malignant germ cell tumors where 
therapy is not complete. 
Chemotherapy can be tried in high grade immature teratomas but response is variable. 
There are a few sequelae of treatment like infertility, ovarian failure, neurogenic bowel and 
bladder and interstitial lung disease which should be kept in mind while treating such patients. 
Long term follow up for sequelae of treatment and recurrence is advisable in patients who have 
immature teratomas or malignant disease. 
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Annexure-1- Information Letter 
 
From 
Department Of Paediatric Surgery 
CMC Vellore 
 
Dear………………….., 
Greetings from Christian Medial College Vellore. 
We have looked at your record and found that you have been treated for Germ Cell Tumor at CMC 
Vellore. 
At present we are undertaking a project to study these tumors in all children who have  suffered from 
similar tumors. 
We would like to have a check up for you in the Paediatric Surgery OPD. along with some blood 
investigations and an X-ray of the chest. This would tell us how you are doing. 
Please do make an appointment for paediatric surgery OPD on any day from Monday to Saturday and 
request the MRO to contact Dr Deepak S Singh. 
We would be obliged if you could consider this as most important. 
This would help us in screening you for any problems and help us in treating patients who suffer from a 
similar tumor. 
If for some reason you are unable to come please do let us know by letter how you are doing. 
 
Thanking You 
 
Yours Sincerely 
 
Dr Deepak Samson Singh 
Mob:+91 8940318971 
 b 
 
Annexure-2 Information sheet and consent Form 
Christian Medical College, Vellore 
Department of Paediatric Surgery 
 Clinical Profile of Children With Extracranial Germ Cell Tumors. 
Information sheet 
 
You/your child are invited to be part of a study to improve the current knowledge about your 
disease condition. This study will help other children who later come to hospital with the same 
complaints.  By agreeing to be a part of this study, you will contribute to recognizing early how 
severe the disease is and thereby starting appropriate treatment immediately. The severity of 
your disease and the final treatment received will be compared to the information collected 
from you in the beginning.  
 
The information collected from you will include  
1. History – This includes details regarding your general health and the  illness 
which you have been treated for 
2. Clinical examination – Includes evaluation by the attending doctor on admission 
to the hospital 
3. Investigations – Includes the results of relevant blood and urine tests, 
radiological investigations, and biopsy reports. 
4. Details of treatment- includes surgery performed, chemotherapy given and post 
treatment follow up 
 
 
Whether you/your child accept or decline to be a part of this study will not affect your further 
treatment at this hospital 
 
The benefits of joining in this study will be that the treating doctor will gain a better 
understanding of your disease and its process thereby help in improving treatment protocols 
for the same. We will also be conducting a blood test and a chest x-ray, free of cost, which is 
part of regular follow up. 
 c 
 
 
There is no disadvantage or complication that can happen to you/your child by participating in 
this study as this study does not interfere in the treatment provided by the care taker. 
  
All details including personal data, assessment of the doctor during and after the operation will 
be kept confidential. 
 
We aim to include about 76 people from this hospital in this study who have been diagnosed to 
have this illness in the last 10 years. 
 
Participation in this study is purely voluntary, and you can withdraw from the study at any time 
and that refusal to participate will not involve any penalty or loss of benefits to which you are 
otherwise entitled. 
 
In case of doubts/ questions, please contact Dr. Deepak Samson Singh, Dept Of Paediatric 
Surgery, CMCH Vellore. Ph no: +918940318971 
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Informed Parental Consent form to Participate in a clinical trial 
Christian Medical College, Vellore 
Department of Paediatric Surgery 
Clinical Profile of Children With Extracranial Germ Cell Tumors 
 
 
Study Number: 
 
Subject’s Initials: _________ Subject’s Name: ________ 
 
Date of Birth / Age:_______ 
 
Please initial box  
 
(i) I confirm that I have read/been read to and understood the information sheet dated 
_________ for the above study and have had the opportunity to ask questions. [ ] 
 
(ii) I understand that my child’s  participation in the study is voluntary and that I am 
free to withdraw at any time, without giving any reason, without my medical care or legal rights 
being affected. [ ] 
 
 (iii) I understand that the Sponsor of the clinical trial, others working on the Sponsor’s behalf, 
the Ethics Committee and the regulatory authorities will not need my permission to look at my 
health records both in respect of the current study and any further research that may be 
conducted in relation to it, even if I withdraw from the trial. I agree to this access. However, I 
understand that my identity will not be revealed in any information released to third parties or 
published. [ ] 
 e 
 
 
(iv) I agree not to restrict the use of any data or results that arise from this study provided such 
a use is only for scientific purpose(s) [ ] 
 
(v) I agree to take part in the above study. [ ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable 
Representative:_____________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
 
Signature of the Witness: ___________________________ 
Date:_____/_____/_______ 
Name of the Witness: ______________________________ 
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Annexure-3 Proforma 
A Clinical Profile of Children With Extra Cranial Germ Cell Tumors 
Hosp No:                                                                                                                                        STUDY No: 
DEMOGRAPHY 
Name:                                              Gender:                                                 Date Of Birth: 
Address:                            
Mobile Telephone:                                                                              
 Patient education status: 
Date of First visit: 
        Other Visits 
 Current Status: Alive and well 
Alive but with complications 
Alive in remission 
 Died- if yes cause of death: Complication of disease, complication of chemotherapy, Complication of 
surgery                    
Abandonment Of Treatment                                                               
Co-morbidities: 
        Other associated anomalies/ Diseases                                          
        OPERATIVE  FINDINGS :   
Type of Surgery: laparoscopic /Open               Date of surgery: 
Size Of mass:                                   Site of Mass:           Findings: 
Post op Complications:                         (Infection / Mortality) 
 
 
 
 g 
 
CLINICAL ASSESSMENT 
Weight                       
Kg 
      
Height/Length          
Cm 
       
Mass        
Abdominal 
distention 
       
Respiratory 
symptoms 
       
Loss of weight        
Loss of apetite        
Bleeding PV        
Mass- site        
Mass- size        
 
Laboratory  ASSESSMENT 
 
Hemoglobin/ 
PCV 
       
Total Counts        
        
Differential 
Counts 
       
        
AFP        
        
Beta HCG        
        
LDH        
        
Creatinine        
        
Electrolytes        
        
        
Ultrasound        
Site Of Mass        
Size of The mass        
        
CT Scan        
Site Of mass        
Size Of mass        
MRI        
POST Chemo and        
 h 
 
surgery imaging 
Biopsy        
Beningn        
Malignant        
elements        
Bone        
cartilage        
Muscle        
Neural        
teeth        
others 
       
Preoperative Chemotherapy 
Admission       
Chemotherapy       
Agents       
Post Op Chemotherapy 
Admission       
Chemotherapy       
Agents       
Outcomes 
Survival 
Disease Free: 
Recurrence: 
Site of Recurrence: 
Abandonment  Of Treatment 
Late Complication: 
Growth 
Respiratory 
Renal 
Death:  
Cause Of death: Complication of disease, Complication Of Surgery, Complication Of Chemotherapy 
Duration of Follow up
 1 
 
 
Master Chart 
      
S No HNUM Gender Age Age code Pathology Biopsy DIAGNOSIS Biopsy no 
1 328914C 2 6 6mths 1 1 Malignant yolk sac tumor Yolk Sac tumor Right Testis 20232/03 
2 427610c 2 12 1yr 1 1 Malignant Germ cell Yolk sac tumor, infiltrating skin yolk sac tumor right testis 3610/04 
3 598476C 2 156 13yrs 1 1 Metastatic Non seminomatous GCT NS GCT, Metastatic 28863/05 
4 673815C 2 24 2yrs 1 1 Endodermal Sinus Tumor Endodermal Sinus Tumor Right Testis-metastatic 18053/05 
5 099477D 2 12 1yr 1 3 Teratoma with focal low grade immaturity ? Teratoma left testis mature 27204/07 
6 056218D 2 36 3yrs 1 1 Yolk sac tumor Yolk Sac Tumor Left Testis 18997/07 
7 218169D 2 168 14yrs 1 2 mature cystic teratoma right scrotum Mature cystic Teratoma Left Testis 11111/08 
8 338781D 2 156 13yrs 1 2 mature cystic teratoma left scrotum Mature teratoma left testis 2361/09 
9 475827D 2 12 1yr 1 2 Bilateral mature teratomas Bilateral testicular teratomas 19243/09 
10 573940D 2 48 4yrs 1 1 Yolk Sac tumor right testis Non Seminomatous GCT -malignant 35517/09 
11 461571D 2 36 3yrs 1 1 Malignant Germ cell Yolk sac tumor, infiltrating skin Recurrent Testicular GCT disemanated ABD 
12 498834D 2 48 4yrs 1 1 Yolk sac tumor Yolk Sac Tumor left testis 22545/09 
13 720167D 2 96 8yrs 1 1 yolk sac tumor Yolk Sac Tumor Right Testis 19954/10 
14 765911D 2 156 13yrs 1 1 embryonal carcinoma lymphovascular invasion GCT- embryonal carcinoma right testis 28013/10 
15 131119F 2 168 14yrs 1 1 mixed GCT with embryonal,yolk sac elemants, immature teratoma GCT- right testis with retroperitoneal lymph nodes 4032/12 
16 155544F 2 36 3yrs 1 1 yolk sac tumor GCT- yols\k sac tumor left testis 9567/12 
17 446196C 2 48 4yrs 1 1 necrotic tumor probably GCT Yolk Sac tumor tesis- undescended testis 9085/04 
18 275668C 1 144 12yrs 2 2 benign cystic teratoma benign teratoma ovary 
 
19 500061c 1 120 10yrs 2 1 mixed GCT ovary Mixed GCT ovary 16951/04 
20 500041c 1 96 8yrs 2 2 mature teratoma right ovary mature cystic teratoma right ovary 18020/04 
21 533791C 1 132 11yrs 2 3 Immature Teratoma Grade II (R) ovarian cyst ? malignant cystic teratoma 25643/04 
22 550245C 1 144 12yrs 2 2 mature teratoma right ovary Right ovarian cyst -  ? teratoma 27967/04 
23 737128C 1 96 8yrs 2 2 mature teratoma left ovary Mature Cystic Teratoma Right Ovary 31407/05 
24 702818A 1 144 12yrs 2 1 mature teratomas with extensive hyalinization Malignant teratoma ovary 709/06 
25 804372C 1 144 12yrs 2 1 dygerminoma right ovary Right Ovarian Dysgerminoma 11550/06 
26 759358C 1 132 11yrs 2 1 mature teratoma right ovary Malignant GCT Ovary 10553/06 
27 132772D 1 48 4yrs 2 2 mature cystic teratoma left ovary Mass per abdomen ? teratoma (L) ovary 32664/07 
28 905136c 1 180 15yrs 2 1 post chemo with scanty viable tumor malignant GCT left ovary 9595/07 
29 041839D 1 84 7yrs 2 1 yolk sac tumor right ovary Yolk sac tumor right ovary 16484/07 
30 108030D 1 72 6yrs 2 2 mature cystic teratoma left ovary Mature teratoma left ovary 28388/07 
31 952629C 1 132 11yrs 2 1 malignant mixed GCT, yolk sac 70%, dysgerminoma 30% Malignant Mixed GCT right ovary 2995/08 
32 511844D 1 96 8yrs 2 1 benign cystic teratoma (R) ovarian mass (cystic teratoma) 26070/09 
33 323734D 1 156 13yrs 2 1 dygerminoma Dysgerminoma right ovary 30031/08 
34 884765B 1 108 9yrs 2 2 mature cystic teratoma right ovary Mature Teratoma Right Ovary 7596/10 
35 715542D 1 144 12yrs 2 2 mature cystic teratoma right ovary Mature Cystic teratoma Right Ovary 20745/10 
36 714822D 1 84 7yrs 2 1 tumor with mature elements post chemo GCT malignant right ovary 31038/10 
37 025340F 1 48 4yrs 2 2 mature cystic teratoma right ovary (R) ovarian mass ? teratoma 29385/11 
38 039126F 1 144 12yrs 2 1 no residual tumor post chemo GCT- malignant right ovarian 1955/12 
39 067044F 1 72 6yrs 2 3 high grade immature teratoma GCT- high grade immature teratoma ovary 35128/11 
40 236942F 1 168 14yrs 2 1 no residual tumor post chemo ovarian teratoma, malignant 33992/12 
41 356203f 1 84 7yrs 2 1 dysgerminoma+ yolk sac /no residual tumor post chemo Mixed GCT dysgerminoma and yolk sac tumor ovary 41129/12 
 2 
 
42 895521C 1 60 5yrs 2 1 no residual tumor post chemo Ovarin GCT-right 17375/12 
43 138014F 1 72 6yrs 2 1 dysgerminoma left ovary Ovarian GCT Left-dysgerminoma 7220/12 
44 796161D 1 84 7yrs 2 1 noresidual tumor/ yolk sac and embryonal elements Left ovarian malignant GCT 30982/11 
45 225912F 1 84 7yrs 2 1 nil viable tumor GCT Ovary 33081/12 
46 746398c 1 60 5yrs 2 1 dysgerminoma Malignant GCT Right Ovary 365/751/06 
47 793022c 1 144 12years 2 1 malignant mixed GCT pred YST, EC, Focal teratomatous Mixed GCT right ovary 10753/06 
48 262524F 1 30 2.5yrs 3 1 malignant neoplasm/ residual mature teratoma post chemo Sacrococcygeal Teratoma-malignant 11104(a) 
49 109013F 2 120 10yrs 3 1 poorly diff malig neo-yolk sac or embryonal ca/myxopapillary ependymoma 
Malignant Presacral Embryonal Carcinoma Status POST 
CHEMO 2256/12 
50 221069F 1 12 1yrs 3 2 mature teratoma 
Neurogenic bladder ,Status opeated case of sacrococcygeal 
teratoma (SCT) ,Recurrent urinary tract infection PS2 
51 227459F 2 12 1yrs 3 1 no residual tumor in the presacral mas, liver biopsy germ cell tumor 
RECURRENT METASTATIC PRESACRAL TERATOMA 
in liver 21645/12 
52 919403D 2 24 2yrs 3 1 teratoma with focal yolk sac/ post chemo focalyolk sac component Sacrococcygeal teratoma with yolk sac tumor 23046/11 
53 675137D 1 2 2mths 3 2 mature teratoma Sacrococcygeal teratoma 11435/10 
54 515866D 1 36 3yrs 3 2 mature teratoma Sacrococcygeal teratoma 28882/09 
55 454699D 1 12 1yrs 3 1 malignanat GCT yolk sac tumor/ no viable tumor post chemo 
Malignant presacral GCT (yolk sac tumour) (presacral 
teratoma) 14703/09,31373/09
56 561376D 1 12 1yrs 3 2 mature cystic teratoma Sacrococcygeal teratoma 35163/09 
57 381557D 1 1day 1day 3 2 mature cystic teratoma Ruptured sacrococcygeal teratoma 259/09 
58 173089D 1 24 2yrs 3 2 mature cystic teratoma Sacrococcygeal teratoma 4406/08 
59 943889C 1 1day 1day 3 3 immature teratoma GIII SCT Immature GIII 36619/06 
60 936427C 1 8 8mth 3 1 malignant neoplasm/ residual mature teratoma post chemo Presacral GCT Malignant 33661/065108/07
61 644385C 1 8 8mths 3 3 immature Teratoma Sacrococcygeal Teartoma immature) 18835/06 
62 855437C 1 84 7yrs 3 2 mature teratoma presacral Teratoma Benign 20763/06 
63 768568C 2 84 7yrs 3 2 maturet teratoma Sacro coccygeal teratoma 3324/06 
64 814878C 2 12 1yrs 3 2 mature cystic teratoma Sacrococcygeal teratoma 12836/06 
65 641470C 1 84 7yrs 3 2 mature cystic teratoma Recurrent sacrococcygeal teratoma 13482/06 
66 743163C 2 4 3.5mth 3 2 mature teratoma  Sacrococcygeal teratoma 31754/05 
67 739333C 1 1day 1day 3 2 mature cytic teratoma Sacro coccygeal teratoma 32017/05 
68 467911C 1 1day 1day 3 2 mature cytic teratoma 
Post op case of sacrococcygeal teratoma excision ,Admitted 
for CIC 13423/04 
69 662165C 1 30 2.5yrs 3 2 mature cystic teratoma Presacral teratoma Altman type III 17941/05 
70 687998C 1 24 2yrs 3 1 malignant gct/no evidence of tumor Malignant GCT Sacrococcygeal 20785/05 
71 947770D 2 108 9yrs 3 2 benign cystic teratoma Excised sacrococcygeal teratoma with neuro vascular weakness of rectal sphincter
72 765226C 1 42 3.5yrs 3 1 malignant gct/mature teratoma Malignant Sacrococcygeal Teratoma 2262/06/11817/06
73 612325C 1 36 3yrs 4 2 mature teratoma Retroperitoneal teratoma 7492/05 
74 698034C 2 96 8yrs 4 2 mature teratoma  Retroperitoneal teratoma 23063/05 
75 886746C 2 16 1.4yr 4 2 
Germ cell tumor consistent with endodermal sinus tumor/ no viable tumor post 
chemo Endodermal Sinus Tumor retroperitoneum 25391/06/953/07
76 009007D 1 24 2yrs 4 2 mature teratoma  Retroperitoneal teratoma (pancreato duodenal region) 10530/07 
77 366976D 1 14 1.2yrs 4 2 monodermal teratoma Retroperitoneal Monodermal Teratoma 38704/08 
78 456626D 2 168 14yrs 4 2 mature teratoma  
Pseudo pancreatic cyst ,Status excision cystic teratoma tail of  
pancreas 16106/09 
79 579839D 2 36 3yrs 4 1 yolk sac tumor Retroperitoneal malignant germ cell tumor metastatic to liver 37285/09 
80 716077D 1 6 6mths 4 2 mature teratoma  (L) retro peritoneal teratoma 20534/10 
81 839820D 2 30 2.5yrs 4 2 mature teratoma  Mature teratoma pelvic mass ( Retroperitoneal 41543/10 
82 852197D 1 60 5yrs 4 1 yolk sac tumor/no viable tumor cells Yolk Sac Tumor right suprarenal region 425/11/11661/11
83 072986F 1 5 5mths 4 3 immature teratoma GCT- high grade teratoma right suprarenal 38338/11 
84 305472f 1 11 11mths 4 2 mature teratoma  Inter aortocaval Teratoma- mature 35035/12 
 3 
 
85 572546D 2 18 1.5yrs 4 1 yolk sac tumor Yolk Sac tumor Left renal Mass 36579/09 
86 192542D 2 36 3yrs 4 2 mature teratoma  Mature Cystic teartoma Head of pancreas 5738/08 
87 144400D 2 7 7mths 4 2 mature teratoma  Mature Teratoma Retroperitoneum 36899/07 
88 075729F 1 6 6mths 4 3 immature  teratoma grade III Immature teratoma retroperitoneum 37528/11 
89 890450D 1 18 1.5yrs 5 2 mature teratoma INTRA  ABDOMINAL TERATOMA 6316/11 
90 288697F 2 156 13yrs 5 3 immature tetratoma containing skin bone hair cartilage and glial tissue Mature teratoma lesser curve of stomach 33835/12 
91 653168D 1 3 2months 5 3 immature teratoma 
Gastric teratoma attached to lesser curve of stomach-
malignant 8411/10 
92 223485C 2 36 3yrs 5 2 mature teratoma 
Subacute intestinal obstruction status exomphalos major with 
benign cystic mature teratoma anterior abdominal  wall 
excision PS1 
93 349659C 2 24 2yrs 5 2 mature teratoma Post op case of benign gastric teratoma with GER PS 
94 545899C 1 8 8mths 5 2 Mature cystic teratoma Benign Cystic Teratoma Liver 27722/04 
95 2396659f 1 168 14years 5 1 Mixed GCT Malignant GCT abdomen 9455a 
96 123496f 2 12 1yrs 6 1 Yolk Sac Tumor Thoracoabdominal yolk sac tumor 14786/12/3085
97 566973D 1 168 14yrs 7 2 mature teratoma Mature teratoma mediastinum 36158/09 
98 252261D 1 120 10yrs 7 2 mature teratoma Mature Cystic Teartoma Thymus 17858/08 
99 155237D 1 36 3yrs 7 2 mature teratoma Anterior mediastinal teratoma 912/08 
100 663388C 1 144 12yrs 7 2 mature cystic teratoma Thymic teratoma ,Mild factor VII deficiency 16913/05 
101 073376F 2 132 11yrs 7 2 mature teratoma MEDIASTINAL TERATOMA 38637/11 
102 440337C 1 72 6yrs 8 2 mature teratoma Rt. cervial teratoma (biospy report awaited) 8206/04 
103 380874D 1 10 10mths 8 1 Malignant yolk sac tumor Yolk Sac tumor Vagina and Cervix 40301/08 
104 696260D 1 7 7mths 8 1 Yolk Sac Tumor GCT Vagina malignant 
 
105 914933D 1 3 2.5mths 8 1 metastatic germ cell tumor right thigh GCT- metastatic GCT from neck 10221/11 
106 760859C 2 24 2yrs 8 2 benign cystic teratoma Benign Cystic Teratoma Left Gluteal 10409/09 
107 696221C 1 136 13yrs 8 1 yolk sac tumor/no residual tumor Malignant GCT Upper lobe left lung 
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<1 
  
2 
 
yes no yes 48 1 Oct-09 Dec-13 1 
 
25.5 
  
2 
 
1 2 yes 48 1 Jan-09 Dec-13 1 
 
<1 
  
2 
 
1 2 yes 60 1 Feb-08 Dec-13 1 
 
<1 
 
no 1,3 
 
yes yes after 5 years yes 72 1 Dec-06 Dec-13 1 
1.3 <1 
 
yes4 1,3 
 
yes yes after 7mths yes 84 1 Nov-06 Dec-13 1 
 5 
 
 
<1 
  
2 
 
yes 2 yes 84 1 Jan-06 Dec-10 1 
 
<1 
  
2 
 
yes no yes 72 1 Jul-06 Dec-13 1 
 
<1 
  
2 
 
1 2 yes 84 1 Feb-06 Dec-10 1 
 
<1 
  
2 
 
1 2 yes 84 1 May-06 Dec-13 1 
 
<1 
  
2 
 
yes 
excised at 12 days of birth, 
recurred yes 84 1 May-05 Dec-08 3 
 
<1 
  
2 
 
1 2 yes 96 1 Dec-05 Dec-10 1 
0.9 4.51 0.65 no 2 
 
yes no yes 96 1 Dec-05 Dec-13 1 
    
2 
 
yes 2 yes 96 1 Apr-05 Dec-10 3 
 
<1 
  
2 
 
yes no yes 96 1 Jul-05 Dec-10 1 
 
<1 
 
yes5 1,3 
 
yes 2 
 
96 1 Jun-05 Dec-08 1 
    
2 
 
1 2 yes 120 1 Sep-11 Dec-13 1 
 
<1 
 
yes4 1,3 
 
yes no yes 84 1 Jan-06 Dec-09 1 
 
,1 
  
2 
 
1 2 yes 96 1 Mar-05 Dec-13 1 
 
<1 
  
2 
 
1 2 yes 96 1 Sep-05 Dec-07 1 
 
7.41 
 
yes 1,3 
 
1 yes yes 12 1 Sep-06 Dec-07 4 
 
<1 
  
2 
 
1 2 
 
72 1 Apr-04 Dec-13 1 
 
<1 
  
2 
 
1 2 
 
60 1 Dec-08 Dec-13 1 
 
<1 
  
2 
 
1 2 yes 48 1 May-09 Dec-13 1 
 
<1 
 
yes 1,4 
 
1 2 
  
1 Nov-09 
 
4 
 
<1 
  
2 
 
1 2 
 
36 1 Jun-10 Dec-13 1 
 
<1 
  
2 
 
1 2 yes 36 1 Dec-10 Dec-13 1 
2.7 <1 
 
yes4 1,3 
 
1 2 yes 24 1 Jan-11 Dec-13 1 
 
<0.1 
 
yes 4 1,3 
 
1 2 yes 24 1 Dec-11 Feb-12 2 
 
<0.1 
  
2 
 
1 2 yes 12 1 Oct-12 Dec-13 1 
0.947 1.5 
 
yes6 1,3 
 
1 2 yes 36 1 Nov-09 Dec-13 1 
 
<1 
  
2 
 
1 2 yes 60 1 Feb-08 Dec-13 1 
 
<1 
  
2 
 
1 2 yes 72 1 Dec-07 Dec-09 1 
 
<0.1 
 
no 1,3 
 
ABD na yes 11 2 Nov-11 Oct-12 2 
 
<1 
  
2 
 
1 2 1 32 1 Feb-11 Dec-13 1 
 
<0.1 
  
2 
 
1 2 1 15 1 Oct-12 Dec-13 1 
4.6 <0.1 
 
2 1,3 
 
1 2 1 48 1 Dec-09 Dec-13 1 
 
<1 
 
2 2 
 
1 2 1 120 1 Nov-04 Dec-13 1 
 
<1 
 
2 2 
 
1 2 1 120 1 Aug-05 Dec-08 1 
 
<1 
  
2 
 
1 2 1 108 1 Nov-04 Dec-08 1 
 
73.39 38.8 yes2 1,3 no ABD 
   
2 Jul-12 
 
2 
6.6 0.1 
 
1 1,3 
 
1 2 1 24 1 Jan-12 Dec-13 1 
 
<1 
 
2 2 
 
1 2 1 48 1 Oct-09 Dec-13 1 
 
1 
 
2 2 
 
1 2 1 60 1 Jun-08 Dec-12 1 
 
<1 
 
2 2 
 
1 2 1 60 1 Jan-08 Dec-13 1 
 
<1 
 
2 2 
 
1 2 1 96 1 Jul-05 Dec-13 1 
 
<0.1 
 
2 2 
 
1 2 1 25 1 Dec-11 Dec-13 1 
 
<1 
  
2 
 
1 2 1 118 1 Apr-04 Dec-10 1 
 
<1 
  
2 
 
1 2 
  
1 Dec-08 
 
2 
 6 
 
 
<1 
 
1 1,3 
 
1 2 
  
1 May-10 Dec-13 1 
 
<1 
 
1 1,3 
 
2 
 
ABD 
 
2 Mar-11 Apr-11 2 
   
2 2 
 
yes no 1 57 1 Jan-08 Dec-13 1 
 
<1 
 
yes4 1,3 
 
1 2 1 96 1 Sep-05 Dec-13 1 
 
Presentation size site Complication of chemo Hb creat USG/CT 
        
right scrotal swelling 10x10 right scrotum nil 
 
12 
 
no mets 
mass abdomen and generalized lymphadenopathy 10x5x5 epigastrium nephrotic symdrome 10.6 0.5 10x5x5 
mass right scrotum 
 
right testis nil 
 
12.2 0.5 normal 
mass left scrotum 2x3 extra testicular nil 
 
13 
 
normal 
mass left scrotum 4x3 left testis asthma 
 
10.9 0.5 right parailiac lymphnodes 
mass right scrotum 6x8 right testis nil 
 
13 
 
multiple cysts in right hemiscrotum testis normal 
mass left scrotum 
 
extra testicular nil 
 
13 
 
extratesticular mass 
bilateral scrotal mass 4x4,5x4 both testis nil 
 
11 0.4 bilateral testicular cystic lesions 
right scrotal swelling 4x4  right testis nil 
 
10.1 
 
right hemiscrotal soft tissue masse 
right scrotal swelling 3x5 right testis 
  
9.9 0.5 mass right scrotum 
left scrotal swelling 3x4 left testis nil 
 
10 0.5 confluent pre and paraaortic LNE 
right scrotal swelling 3x2 right testis nil 
 
9.9 0.6 confluent paraaortic nodes 
right scrotal swelling 6x6 right testis nil 
 
13 0.8 heterogenous right testis 
right testicular tumor 5x6cm right testis nil 
 
10.8 0.6 confluent necrotic mass from renal hilum to bifurcation of aorta 
left scrotal swelling 5cm left testis nil 
 
11.1 0.6 no evidence of intrabdominal mets 
vomiting and pain 5cm right undescended testis nil 
 
10 0.4 6x6 cm retroperitoneal mass 
abdominal mass 30x15 left ovary nil 
 
12 0.3 large retrperitoneal mass 
abdominal mass 10x5 right ovary nil 
 
12 0.4 normal 
abdominal mass 6x6x4 right ovary nil 
 
10 0.5 6.6x4.6x5.6cm mass - complicted cyst  
    
 
   
abdominal mass, pain 9x6 right ovary nil 
 
10 0.7 7.3x5x4.5 cm mass in POD 
pain abdomen, mass 8x4 left ovary nil 
 
14 0.7 left ovarian cyst 
mass, ascitis 10x10 right ovary nil 
 
11.5 0.7 right ovarian cyst multiloculated compressing both ureters 
mass 19x14 right ovary nil 
 
12 0.7 19x14x6cm mass right ovary 
mass pain 15x7 right ovary nil 
 
10 0.6 15x7x6 cm tumor arising from pelvis, R HUN 
mass.pain 7x5 left ovary nil 
 
11 0.5 8x7cm mass arising from left ovary 
mass fever loss of wt pain 
 
left ovary nil 
 
12 0.5 7.9x4.9x9.5 mass pelvis left ovary 
mass pain 7x10 right ovary nil 
 
10 0.4 7x8x10cm mass right adenexa 
pain abdomen 
 
left ovary nil 
 
10 
 
3x4x3 cm left ovary 
pain abdomen 13x14 right ovary 
 
 
8.2 0.5 13x3x14 pelvic mass 
pain and vomiting 10x6 right ovary nil 
 
11 0.6 10x7x5cm mass with calcification and fat 
pain abdomen 10x10 right ovary nil 
 
10 0.6 10x14x10 cm heterogenous mass in pelvis 
pain and vomiting 5x7cm right ovary nil 
 
12 0.6 
 
pain and vomiting 7x5 right ovary nil 
 
12 0.6 7x4.9cm mass right ovary cystic 
pain and vomiting and fever 9x13 right ovary nil 
 
8.8 0.6 9x15 mass right ovary 
 7 
 
pain  4x3 right ovary nil 
 
12 0.5 4.6x3.5 cm mass right ovary 
pain and mass 20x15 right ovary nil 
 
10 0.7 15x12x10cm mass in pelvis with central necrosis and right HDN,  
pain and mass 5x5 right ovary nil 
 
11 0.7 5x5cm mass right ovary 
mass ,distention fever 22x16 right ovary nil 
 
7.6 0.6 16x22 cm complex cyst arising from pelvis 
mass 11x9 right ovary nil 
 
10 0.6 11x9 cm mass right ovary 
pain and mass 10x7 right ovary nil 
 
13 0.5 10x7x5cm mass right ovary, 2 other lesions posterior to it 
pain 7x7 left ovary nil 
 
11 0.5 5x7 mass left ovary 
mass 5x5 left ovary nil 
 
10 0.4 11x10cm mass arising from left ovary 
pain abdomen 12x10 right ovary nil 
 
13.4 0.4 normal 
mass 7x8 right ovary nil 
 
12 0.6 mass right adenexa 
mass 7x6 right ovary nil 
 
11 0.7 mass right ovary 
mass 5x4.5 presacral  nil 
 
8.8 0.4 presacral mass with superficial component, no liver mets 
pain  3.8x1.4 presacral  nil 
 
12 0.7 presacral mass38x14 mm 
mass 10x12 sacrococygeal nil 
 
12 0.5 nil 
mass 5x3 presacral  nil 
 
8.8 0.5 recurrent mass presacral regio with lung and liver mets 
mass right gluteal region and paraparesis 10x12 right gluteal region nil 
 
9.1 0.4 10x12cm presacral mass 
mass sacrococygeal 7x5 sacrococygeal nil 
 
12 0.4 
 
mass sacrococcygeal 6x4 sacrococygeal nil 
 
11 
 
6.3x4.4x7.6cm mass in sacrocosccygealregion with minimal presacral ext
mass sacrococcygeal 3x3cm sacrococygeal nil 
 
10 0.4 7x 7 cm mass extending to L4 and below the coccyx lung mets 
sct mass 3x3cm sacrococygeal nil 
 
12 0.4 5x9x4 cm mass extending from L5 S1 level to perineum 
sct mass 10x10 sacrococygeal nil 
 
17 0.4 
 
sct mass 20x20cm sacrococygeal nil 
 
12 0.5 
14x8x10 cm mass with large presacral component and external component extending from S1 to 
perineum 
sct mass 10x7 sacrococygeal nil 
 
14 0.4 10x7 cm mass with minimal intrapelvic extension 
sct mass operated at 12 days of life recurred 4x4 sacrococygeal nil 
 
11.5 0.6 1.7x2.6x1.5cm mass anterior to rectum 
sct mass 3x2 sacrococygeal nil 
 
12 
 
2x1cm mass 
sct mass 5x4.5 sacrococygeal nil 
 
12 0.6 5.2x4.3x5.4 cm mass in the presacral area 
sct mass 3x3cm sacrococygeal nil 
 
13 
 
4x3 cm mass presacral region 
sct mass 5x4 sacrococygeal nil 
 
13 0.4 1.9x2x2.9cm lesion in sacrococcygeal region 
mass with discharge from multiple sinuses 5x15x20 sacrococygeal nil 
 
12 0.5 16x11x7cm mass in intergluteal cleft with cystic areas 
mass in the sct with 15x15 sacrococygeal nil 
 
9 0.5 9.5x5.7 cm mass in sacral region 
mass sct 5x7 sacrococygeal nil 
 
20 0.6 
 
mass sct 10x12 sacrococygeal nil 
 
14 0.4 15x10 cm mass extending from aortic bifurcation to perineum 
mass sct 4x2 sacrococygeal nil 
 
  
13x8.7x8 cm mass from pelvis to the ischium 
mass sct sudden increase in size 8x8x6 sacrococygeal nil 
 
9.9 0.4 10x5x7 cm mass which is predominantly presacral 
mass sct 10x12 sacrococygeal nil 
 
13 0.6 
 
mass sct biopsied outside 5x15x20 sacrococygeal nil 
 
9.6 0.4 5.1x4.5x3.4cm mass in the perineum with intrapelvic extension and displacing rectum to the right
mass distention abdomen left hypochondrium retroperitoneum 
     
mass distention abdomen 8x4x2cm lesser sac nil 
 
13 0.6 mass in the lesser sac measuring  
mass distention abdomen paraparesis 15x9x9.4cm 
retroperitoneum extending to 
thorax nil 
 
8.9 0.4 mass retroperitoneum 15x9x9.4cm extending into thorax, extending into spinal canal T11 ato L1
mass and distention of abdomen 15x10 lesser sac nil 
 
12 
 
15x10x8 cm mass in lesser sac 
mass and distention of abdomen 15x12 retroperitoneum nil 
 
11.9 0.4 12x8.9cm multiloculated cyst compressing kidney and causing hDN 
mass and distention of abdomen 11x10 tail of pancreas nil 
 
13 0.6 11x10x8 cm mass in the region of tail of pancreaas 
pain and distention fever multtiple retroperitoneum  mets in liver niil 
 
12 0.7 multiple large confluent masses 13x12x8.5cm 
 8 
 
mass left abdomen 15x15 retroperitoneum nil 
 
12 0.5 10x8cm mass in the left retroperitoneum with solid and cystic components
left abdominal mass 10x10 retroperitoneum nil 
 
12 0.6 12x9x13cm mass occupying the abdomen and pelvis with left HUN 
pain and distentionand vomiting 14x10 right suprarenal region nil 
 
12 0.4 14x10x9.5cm mass in the right suprarenal region with central necrosis 
abdominal mass 8x6 right suprarenal region nil 
 
11 0.4 8.3x6.1x8cm mass in the right suprarenal region 
mass abdomen and UTI 10x10 interaortocaval nil 
 
14 0.3 10x10x8cm mass in the interaortocaval region from abdomen to pelvis
pain abdomen and mass 13x11 left kidney nil 
 
12 0.5 13x11cm mass arising in left kidney 
abdominal pain 6x4 hepatoduodenal ligament nil 
 
  
6.9x4.1x4.5cm mass in the hepatoduodenal ligament 
mass 10x12 
left sided retroperitoneal 
tumor nil 
 
12 0.4 ascitis with septations and internal echoes 
mass abdomen 6x10 right hypochondrium non response to chemo 12 0.3 large intrabdominal lesion with septated cystic and echogenic areas 
distention 5x5 retroperitoneal nil 
 
10 0.5 retroperitoneal teratoma 
pain abdomen 8x7 anterior wall of stomach nil 
 
10.8 0.6 8x7 cm mass anterior to stomach and pancreas with calcification 
mass  16x9x7 posterior wall of stomach nil 
 
10 0.4 large heterogenous mass in the upper abdomen 
exomphalos 5x6 anterior abdominal wall nil 
 
10 0.5 mass abdominal wall 
mass  5x7 anterior wall of stomach nil 
 
10 0.4 mass abdomen 
mass and distention 16x10 liver nil 
 
10 0.4 cystic mass 10x9x9.5 exophytically arising from left lobe of liver 
mass 
occupying most of 
abdomen abdomen DiedJul2012 
    
breathing difficulty, abd distention 12x10 right thorax and abdomen nil 
 
11 0.4 Mass in the posterior mediatinum extending into abdome 
pain right chest 7.3x7 anterior mediastinum nil 
 
14 0.6 mass in anterior mediastinum measurin 7.7x7.3 cm 
loss of apetite, fever 8x8 mediastinum nil 
 
14 0.5 mass in the posterior mediastinum withattachment to thymus 
abdominal pain 10x8 anterior mediastinum nil 
 
12.6 0.4 mass in anterior mediastinum measuring 12x10x8 cm 
respiratory distress 8x5 anterior mediastinum nil 
 
12 0.4 mass 7.8x5.3 cm in anterior mediastinum 
hemoptysis 4x5 anterior mediastinum nil 
 
14 0.5 mass attached to pericardium in left anterior mediastinum 
mass right neck since birth 10x12 right side of neck nil 
 
   
   
nil 
 
   
bleeding pv 4x3 bladder and cervix nil 
 
12 0.4 mass occupying the vagina and the uterus 
mass right neck, given bleo, affecte eye movement mass left 
thigh 20x20 neck  
 
 
8 0.4 mass  right neck  
recurrent mass left gluteal region 3x3 left gluteal nil 
 
12 0.6 mass left gluteal region cystic  
Fever and cough  Sep-05 left lung upper lobe nil 
 
11 0.6 15x13x9 cm mass occupying left thorax 
 
op findings Biopsy Ht wt 
Altma
n Type 
Follo
w up 
ht 
Follo
w up 
wt 
       
enlarged right testis Malignant Germ cell Yolk sac tumor, infiltrating skin 
     
Mass abdomen Metastatic Non seminomatous GCT 
     
enlarged tight testis Endodermal Sinus Tumor 75 9.1 
   
enlarged left testis Teratoma with focal low grade immaturity 
     
enlarged left testis Yolk sac tumor 90 13.2 
 
112 19.6 
enlarge right testis mature cystic teratoma right scrotum 
     
mass left testis mature cystic teratoma left scrotum 120 30 
 
176 45.9 
enlarged bilateral testis Bilateral mature teratomas 
     
enlarged right testis Yolk Sac tumor right testis 108 17.2 
 
116 20.2 
enlarged right testis Malignant Germ cell Yolk sac tumor, infiltrating skin 
 
10 
   
enlargde left testis Yolk sac tumor 99 13.2 
   
 9 
 
enlarged right testis yolk sac tumor 125 19 
 
141 27.9 
enlarged right testis embryonal carcinoma lymphovascular invasion 157 40.6 
 
167 48.9 
enlarged right testis 
mixed GCT with embryonal,yolk sac elemants, 
immature teratoma 156 46 
 
164 53.5 
enlarged left testis yolk sac tumor 96 14 
   
torted right testis with tumor in pelvis with adhesions necrotic tumor probably GCT 
   
118 20.3 
large ovarian cyst 30x15cm benign cystic teratoma 
     
large ovarian mass in right ovary mixed GCT ovary 
     
8x8cm tumor right ovary mature teratoma right ovary 
     
mass occupying most of abdomen 
      
9x6cm tumor right ovary mature teratoma right ovary 
     
6x7 cm mass left ovary mature teratoma left ovary 140 33 
 
153 40.8 
large ovarian mass in right ovary mature teratomas with extensive hyalinization 156 38 
 
168 55.5 
19x14x6cm mass  dygerminoma right ovary 133 28 
   
large ovarian mass, ascitis mature teratoma right ovary 146 30 
 
164 70 
twisted left ovarian mass mature cystic teratoma left ovary 
     
10x8 cm left ovarian mass adherent to omentum post chemo with scanty viable tumor 150 31.6 
   
10x8 cm right ovarian mass adherent to omentum yolk sac tumor right ovary 
 
14 
   
3x4x3 cm mass left ovary mature cystic teratoma left ovary 135 20.8 
   
15x14cm mass right ovary 
malignant mixed GCT, yolk sac 70%, dysgerminoma 
30% 145 34 
   
10x8cm mass benign cystic teratoma 143 25 
 
155 33 
10x10cm mass with torsion right ovary dygerminoma 153 38 
 
157 37 
7x8cm torted ovary with gangrene of fallopian tube mature cystic teratoma right ovary 
   
139 30 
7x5cm mass right ovary mature cystic teratoma right ovary 
     
15x12x5cm right ovarian mass tumor with mature elements post chemo 126 26 
 
131 35 
4x3 cm mass right ovary mature cystic teratoma right ovary 126 26 
   
8x8x6cm mass right ovary no residual tumor post chemo 149 30.6 
 
150 32 
5x4 cm mass right ovary high grade immature teratoma 
     
10x8cm mass adherent to omentum no residual tumor post chemo 150 40 
 
151 36 
5x3 cm mass with nodules in the retroperitoneum dysgerminoma+ yolk sac /no residual tumor post chemo 125 20.7 
 
126 20 
2x1.5cm mass in the right ovary no residual tumor post chemo 100 16 
 
126 20 
5x7 cm mass left ovary with torsion dysgerminoma left ovary 125 25 
 
126 35 
5x5xm left ovarian mass noresidual tumor/ yolk sac and embryonal elements 115 17 
 
121 18 
mass of right ovary adherent to sigmoid and deposits in the pelvic wall nil viable tumor 103 13.9 
 
102 13.2 
7x8cm right no viable tumor 
     
7x5cm mass right ovary no viable tumor 
     
 
mass in the presacral region 
malignant neoplasm/ residual mature 
teratoma post chemo 82 III 8.8 93 
 
fibrosis in presacral region 
poorly diff malig neo-yolk sac or 
embryonal ca/myxopapillary 
ependymoma 140 IV 28.2 144 
 
sacrococcygeal mass with bone and cartilage and hair mature teratoma 88 I 12 100 
no active residual disease although residual masses present fibrosed mass in presacrum, mets in segment 5 and 6 
no residual tumor in the presacral mas, 
liver biopsy germ cell tumor 89 IV 10.5 98 
 
large mass involving the presacrum 5x5 cm 
teratoma with focal yolk sac/ post chemo 
focalyolk sac component 78 II 10.3 
 
 
7x 5cm mass with minimal presacral extension mature teratoma I 
  
 
7x5cm mass with minml presacral ext mature teratoma I 
  
no active residual disease although residual masses present 7x3 cm mass lefrt pelvic wall 
malignanat GCT yolk sac tumor/ no 
viable tumor post chemo 84 III 10.6 100 
 10 
 
 
9x7 cm mass in the presacral region mature cystic teratoma III 
  
 
10x10 cm mass with minimal presacral extension mature cystic teratoma I 
  
 
large mass with presacral extension  mature cystic teratoma II 
  
 
SCT with  minimal presacral ext, spillage of tumor into the wound/ residual mass in right parailiac 
regionand iliac nodes/ mass in the parailiac region and nodes 101 I 15 
 
no evidence of osseous mets 2x3x2cm mass anterior t sacrum 
malignant neoplasm/ residual mature 
teratoma post chemo 67 III 9 104 
 
2x3 cm mass inferior to coccyx immature Teratoma I 
  
 
5x4x5 cm large cyst and a 2x3 cm smaller cyst in the 
presacral area mature teratoma II 
  
 
4x4 cm mass in the presacral area attached to coccyx maturet teratoma II 
  
 
1.5x5cm mass in presacral area 
  
II 
  
 
15x15cm fleshy sacroccygeal mass containing cheesy 
material mature cystic teratoma I 
  
 
10x7 cm mass in the sct mature teratoma  I 
  
 
5x7x5cm mass in the sacral region mature cytic teratoma I 
  
 
large cystic mass in the sacral and presacral region mature cytic teratoma II 
  
 
mass in the presacral region measuring 13x8x9 cm mature cystic teratoma III 
  
 
mass with external componenet 4x3 cm densely adherent 
to posterior and right rectal wall and coccyx malignant gct/no evidence of tumor 78 III 8 85 
 
mass in the sacrococygeal region benign cystic teratoma I 
  
 
mass fixed to overlying skin and to coccyx malignant gct/mature teratoma 91 II 10.5 108 
well encapsulated mass behind left colon 
      
cystic lesion adherent to the head of pancreas. mature teratoma  
     
hard mass adherent from T6-T8 infiltrating  Germ cell tumor consistent with endodermal sinus tumor/ no viable tumor post chemo paraparesis 
mass in lesser sac in the pancreaticoduodenal region mature teratoma  
     
large mass pushing sigmoid and descending colon medially monodermal teratoma 
     
large cyst filled with debri with cartilage and hair, between transverse 
mesocolon and tail of pancreas mature teratoma  161 36 
   
 
yolk sac tumor 
     
15x15cm mass osterior to the left transverse colon mature teratoma  
     
10x8 cm mass in the retroperitoneum extending from bladder to the left 
kidney mature teratoma  69 7.7 
 
75 8.9 
7x6x8cm mass in the yolk sac tumor/no viable tumor cells 50 11 
   
large cystic mass from the undersurface of liver to just above the pelvis immature teratoma 63 5.5 
   
large retroperitoneal interaortocaval tumor from infradudenal ivc to the 
pelvis mature teratoma  69 7.2 
 
100 12 
tumor arising from the upper pole of left kidney6x5x5cm yolk sac tumor 75 
10.4
2 
   
cystic mass head of pancreas mature teratoma  
     
mass in the retroperitoneum left of the spine mature teratoma  
     
large cystic mass adherent to liver splaying the right and left renal veins 
and IVC. Pushing duodenum and right kidney inferiorly immature  teratoma grade III 
 
6.8 
   
  
60 13 
 
80 15 
tumor adherent to liver arising from lesser curve of stomach mature teratoma 
     
huge cystic tumor attached to the posterior wall of the stomach 
immature tetratoma containing skin bone hair cartilage 
and glial tissue 60 3.1 
 
82 9.8 
large antreior abdominal wall defect with a mass containing hetrogenous 
cyst mature teratoma 45 3 
 
150 35 
large mass attached to stomachwall mature teratoma 40 3 
 
101 16 
15x8cm loculated tumor in the left lobe of liver 
 
40 3 
 
140 35 
       
retroperitoneal tumor adherent to right lobe of liver extending to right 
thorax through a diaphragmatic defect yolk sac tumor/ no residual tumor post chemo 76 7.7 
 
87 9.6 
2 cyts interconnected containing hair and soft tissue mature teratoma 135 35 
 
150 55 
8x8 cm mass anterior to thoracic aorta attached to thymus mature teratoma 135 32 
 
150 45 
 11 
 
15x10cm mass in anterior mediastinum collapse of lung mature teratoma 120 25 
 
134 30 
4x5cm mass in the anterior  mediastinum attached left lung and 
pericardium mature cystic teratoma 135 35 
 
150 50 
5x5 cm mass arisinf from left lat aspect of thymus with cheesy materieal 
and fine hair mature teratoma 163 41 
 
167 45 
10x12 cm cyst adherent to right cheek intraoral and sternomasroid mature teratoma 
     
       
  
67 6.7 
 
78 11.4 
nil metastatic germ cell tumor right thigh 
     
3x3 cm cystic mass containing bone and hair benign cystic teratoma 86.5 11.4 
   
Mass upper lobe of left lung yolk sac tumor/no residual tumor 146 39 
 
151 58 
 
 



